{"meta":{"query_hash":"4ceb0606b211","filters":{"venue":"HIV Clinical Trials"},"cohort_total":57,"direct_labels_cover":4,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4ceb0606b211","api":"https://metacan.xera.ac/api/v1/cohort?venue=HIV+Clinical+Trials"},"results":[{"id":"W118439278","doi":"10.1310/m0cv-r6bx-a9dp-jjv0","title":"Circulating Levels of IL-7 but not IL-15, IGF-1, and TGF-β Are Elevated During Primary HIV-1 Infection","year":2004,"lang":"en","type":"letter","venue":"HIV Clinical Trials","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Transforming growth factor; Human immunodeficiency virus (HIV); Immunology; Virology; Internal medicine","score_opus":0.14433336507600897,"score_gpt":0.36135788290214543,"score_spread":0.21702451782613646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W118439278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89808095,0.0013060358,0.0006653021,0.064333424,0.030352453,0.0021613934,0.0011215995,0.0004658487,0.0015129696],"genre_scores_gemma":[0.6493788,0.0026941607,0.0002954654,0.22440016,0.012326583,0.00019771364,0.0077777463,0.00040209573,0.10252728],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915612,0.0033540307,0.0036419772,0.0008329302,0.00012101862,0.0004888749],"domain_scores_gemma":[0.9915828,0.0044435514,0.003109249,0.00056227064,0.00026570767,0.00003640549],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0037830512,0.0005145236,0.0024182172,0.00032636555,0.00025319154,0.000045876477,0.00018695966,0.0030257637,0.002036876],"category_scores_gemma":[0.0076603773,0.00046764346,0.00090236694,0.00016027525,0.00032790293,0.00018560549,0.0001569044,0.0034418006,0.0008542298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019647728,0.00030733304,0.0029605124,0.00095473934,0.0017942919,0.000092621034,0.000091302725,0.000024106896,0.55351204,0.000019810237,0.43526676,0.0030117396],"study_design_scores_gemma":[0.015767474,0.00064235664,0.10226542,0.0019577849,0.00116287,0.0004723214,0.00006688216,0.0000056700733,0.10301739,0.00016908917,0.77323693,0.0012358424],"about_ca_topic_score_codex":0.00007927782,"about_ca_topic_score_gemma":0.0000032878381,"teacher_disagreement_score":0.45049465,"about_ca_system_score_codex":0.00017553939,"about_ca_system_score_gemma":0.0002310029,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W1963635957","doi":"10.1310/hct0902-73","title":"Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients","year":2008,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tolerability; Enfuvirtide; Dosing; Regimen; Adverse effect; Pharmacokinetics; Internal medicine; Pharmacology; Immunology","score_opus":0.1454580302820737,"score_gpt":0.40894059936397603,"score_spread":0.2634825690819023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963635957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946424,0.00029139064,0.000068185574,0.0007472218,0.0006371714,0.0013873569,0.00006214013,0.000056564433,0.002107613],"genre_scores_gemma":[0.99431044,0.00095019094,0.0031942176,0.00009098261,0.00026623925,0.000018337882,0.00016898976,0.00004313164,0.0009574428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933258,0.0012325968,0.0037700278,0.00061531283,0.000603981,0.00045224465],"domain_scores_gemma":[0.9892284,0.00863451,0.001126771,0.00047196719,0.0002149424,0.0003233996],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035445003,0.000373677,0.0024097327,0.00028825752,0.00011005099,0.000013120017,0.00014022528,0.00033606729,0.00016329183],"category_scores_gemma":[0.01298233,0.00030029807,0.00042081275,0.00049926795,0.00038406576,0.00012366578,0.00012255846,0.00041937947,0.00008420866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052944794,0.0043263333,0.9012566,0.00018283077,0.00097408245,0.00014521886,0.0017315958,0.000010187243,0.0019097545,0.00010190303,0.0045233746,0.03189329],"study_design_scores_gemma":[0.17025967,0.0015882544,0.8142516,0.0014485848,0.00088895345,0.00000803657,0.00012385318,0.00010288656,0.0033370373,0.00003930098,0.0075080483,0.0004437754],"about_ca_topic_score_codex":0.000041567735,"about_ca_topic_score_gemma":0.000014122353,"teacher_disagreement_score":0.11731487,"about_ca_system_score_codex":0.00013665708,"about_ca_system_score_gemma":0.00035414743,"threshold_uncertainty_score":0.9999449},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W1965528887","doi":"10.1310/q2l2-qvrk-4e01-c8f8","title":"Progression to AIDS or Death as Endpoints in HIV Clinical Trials","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Medicine; Regimen; Internal medicine; Clinical endpoint; Clinical trial; Cohort; Antiretroviral therapy; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Viral load; Oncology; Immunology","score_opus":0.5056012280870779,"score_gpt":0.6012395459815103,"score_spread":0.09563831789443245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965528887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97317314,0.0021840767,0.00059013575,0.0069049927,0.003853504,0.0059963884,0.0004890105,0.00023557656,0.00657318],"genre_scores_gemma":[0.9483769,0.005553393,0.00402192,0.00216159,0.0019628583,0.00086098386,0.0007788482,0.00008825396,0.03619529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9576506,0.033235397,0.0066900984,0.0011456613,0.00021097441,0.0010672656],"domain_scores_gemma":[0.9450092,0.052391056,0.0009719448,0.0009783648,0.00014585923,0.00050361024],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.08442882,0.00041487935,0.0037598144,0.0002905414,0.0001699371,0.000060343827,0.00058085786,0.001148727,0.010402993],"category_scores_gemma":[0.19479777,0.00024674658,0.0012432097,0.00042579617,0.00030630018,0.00010834738,0.0003208239,0.0011474862,0.03894016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05336245,0.0054375925,0.2584824,0.000018464669,0.0010850076,0.0009951411,0.000107911874,0.0000015536756,0.0026867334,0.0005478979,0.08808012,0.5891947],"study_design_scores_gemma":[0.066346906,0.012420515,0.07841518,0.00056081265,0.00040915096,0.00014376985,0.00018475944,0.000003922643,0.0055660577,0.0015579992,0.8336598,0.00073108147],"about_ca_topic_score_codex":0.000042130956,"about_ca_topic_score_gemma":0.000056719167,"teacher_disagreement_score":0.7455797,"about_ca_system_score_codex":0.00008217888,"about_ca_system_score_gemma":0.0006091676,"threshold_uncertainty_score":0.99999845},"labels":[],"label_agreement":null},{"id":"W1965948300","doi":"10.1310/hct1104-186","title":"Randomized, Comparative, Double-Blind, Double-Dummy, Multicenter Trial of Miconazole Buccal Tablet and Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis: Study of Miconazole Lauriad<sup>®</sup>Efficacy and Safety (SMiLES)","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS oral health manifestations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Miconazole; Clotrimazole; Buccal administration; Clinical trial; Randomized controlled trial; Adverse effect; Internal medicine; Pharmacology; Antifungal; Dermatology","score_opus":0.2931300087889962,"score_gpt":0.5013441931525906,"score_spread":0.2082141843635944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965948300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97512406,0.0008441923,0.00009643564,0.0010357487,0.000495479,0.021702599,0.00057369424,0.000026322436,0.000101474885],"genre_scores_gemma":[0.9947226,0.0016829326,0.0012364151,0.00007807787,0.00088077993,0.0009389549,0.0001544922,0.00003524864,0.00027049775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915392,0.0017558718,0.005142385,0.0006542102,0.0004731055,0.00043526856],"domain_scores_gemma":[0.9633197,0.03330455,0.0018136244,0.0007049746,0.00045162655,0.00040550926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008979245,0.0004440513,0.00506248,0.00024202764,0.00019574126,0.000030140733,0.0002240819,0.00032942693,0.00008437647],"category_scores_gemma":[0.0023684853,0.00027111024,0.0006968515,0.00025943381,0.0009703972,0.00013390262,0.0000769407,0.00041185404,0.000002411609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97564507,0.011571099,0.0030837092,0.00023944097,0.0014588311,0.0000035870212,0.0038214263,0.00004915842,0.00053986034,0.00034240523,0.0005396257,0.00270579],"study_design_scores_gemma":[0.97540486,0.00924892,0.0018589172,0.00010809018,0.0038004976,0.0000060170723,0.0025692584,0.002179336,0.0016516637,0.00002711578,0.0029371916,0.00020810831],"about_ca_topic_score_codex":0.0007763347,"about_ca_topic_score_gemma":0.00040449944,"teacher_disagreement_score":0.03154868,"about_ca_system_score_codex":0.000037632024,"about_ca_system_score_gemma":0.0004124122,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W1970014945","doi":"10.1310/xp75-7vj5-hml2-yf1w","title":"Update on HIV Lipodystrophy","year":2004,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Lipodystrophy; Medicine; Antiretroviral therapy; Adverse effect; Human immunodeficiency virus (HIV); Pathogenesis; Intensive care medicine; Immunology; Internal medicine; Viral load","score_opus":0.4353347746231593,"score_gpt":0.579937942091974,"score_spread":0.14460316746881474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970014945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004069758,0.98696166,0.00007507969,0.0017974551,0.0009826404,0.00387971,0.00051946397,0.0001667356,0.0056132055],"genre_scores_gemma":[0.0000062102663,0.9882231,0.0014537624,0.0006892328,0.0020173795,0.0003872163,0.0016948597,0.000110645415,0.005417639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99061555,0.0020901337,0.0054277424,0.0009850046,0.00040455474,0.0004770457],"domain_scores_gemma":[0.9902054,0.005564462,0.0018727427,0.0015040973,0.00011907237,0.00073420646],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004659165,0.0006122774,0.007572751,0.00027520303,0.00014822767,0.000032989337,0.0002782907,0.0012163237,0.0008793502],"category_scores_gemma":[0.005612366,0.0003924091,0.0029355225,0.0004227424,0.00011805948,0.000027200747,0.0000634106,0.0015351219,0.03293727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017197656,0.0012781651,0.000014095962,0.0059200237,0.0009281529,0.00013480514,0.000003362333,4.6967565e-7,1.0217876e-8,0.001676878,0.025435641,0.9644364],"study_design_scores_gemma":[0.0043416894,0.00072570797,0.000021987204,0.038813926,0.0048793224,0.000049670758,8.6010664e-7,0.0000013495936,6.9904395e-8,0.00028983533,0.9506218,0.0002537926],"about_ca_topic_score_codex":0.000004431748,"about_ca_topic_score_gemma":2.5861127e-7,"teacher_disagreement_score":0.9641826,"about_ca_system_score_codex":0.00030874967,"about_ca_system_score_gemma":0.0015708728,"threshold_uncertainty_score":0.9998528},"labels":[],"label_agreement":null},{"id":"W1970660282","doi":"10.1310/9m23-qn0x-w6n8-80jd","title":"Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Lunenfeld-Tanenbaum Research Institute; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Cytomegalovirus retinitis; Medicine; Discontinuation; Retinitis; Maintenance therapy; Cohort; Internal medicine; Cytomegalovirus; Prospective cohort study; Immunology; Human cytomegalovirus; Viral disease; Human immunodeficiency virus (HIV); Herpesviridae; Chemotherapy; Virus","score_opus":0.11841626984675059,"score_gpt":0.42888575966109255,"score_spread":0.31046948981434197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970660282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99044955,0.00031323222,0.00059046503,0.00037860346,0.00047892684,0.0044119563,0.0012511632,0.00004926436,0.0020768326],"genre_scores_gemma":[0.99115753,0.0012008162,0.00039055827,0.00015249643,0.0008505351,0.0002019265,0.0005019278,0.00007632889,0.005467892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99305683,0.0009460455,0.0039653056,0.00065745064,0.000763735,0.0006106004],"domain_scores_gemma":[0.99071074,0.0057836385,0.0014400824,0.0007792753,0.0010224609,0.00026381412],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0074417302,0.00033460654,0.0031173702,0.00023591242,0.00007392991,0.000033251083,0.00029808417,0.00040429056,0.0005586033],"category_scores_gemma":[0.012022831,0.00024672842,0.0015424719,0.00041088104,0.0004767981,0.00010395504,0.00008730628,0.00039374272,0.000050643986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019874727,0.0017160971,0.9323669,0.00019268454,0.0005732916,0.000015302167,0.000036412497,5.9187545e-7,0.0026160951,0.00021977146,0.023700818,0.018687313],"study_design_scores_gemma":[0.047805972,0.0020481842,0.9295969,0.00052723236,0.0003124046,0.0000022661743,0.000006697499,0.0000374321,0.0077084685,0.0002575614,0.011441449,0.00025545774],"about_ca_topic_score_codex":0.0001777386,"about_ca_topic_score_gemma":0.00007164212,"teacher_disagreement_score":0.027931245,"about_ca_system_score_codex":0.00006109763,"about_ca_system_score_gemma":0.0003112476,"threshold_uncertainty_score":0.9999985},"labels":[],"label_agreement":null},{"id":"W1971304024","doi":"10.1310/hct0801-36","title":"Virologic and Immunologic Impact and Durability of Enfuvirtide-Based Antiretroviral Therapy in HIV-Infected Treatment-Experienced Patients in a Clinical Setting","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Maple Leaf Medical Clinic","funders":"Canadian Institutes of Health Research","keywords":"Enfuvirtide; Medicine; Interquartile range; Viral load; Discontinuation; Internal medicine; Regimen; Hazard ratio; Retrospective cohort study; Adverse effect; Salvage therapy; Gastroenterology; Human immunodeficiency virus (HIV); Confidence interval; Immunology; Chemotherapy","score_opus":0.13038906756558047,"score_gpt":0.4729908189783467,"score_spread":0.3426017514127663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971304024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972648,0.0003262053,0.000017220114,0.00038284523,0.00011243133,0.0017459819,0.00002683559,0.0000399244,0.00008373555],"genre_scores_gemma":[0.9976645,0.0009721157,0.000997902,0.00012946113,0.00005967187,0.000039113143,0.00006937042,0.000015723295,0.000052108946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99280286,0.0021826753,0.0036559582,0.0006741025,0.00022594229,0.0004584587],"domain_scores_gemma":[0.9888095,0.009808045,0.0007380227,0.00034884454,0.000076239456,0.00021932177],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012005878,0.00034134375,0.002166146,0.0002607074,0.000046759185,0.00001604749,0.00007815724,0.00041340844,0.00007485234],"category_scores_gemma":[0.012204996,0.00020970563,0.0004273529,0.0003586247,0.00048263164,0.00008270509,0.00004747284,0.00034073275,0.000007847741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008532721,0.003375471,0.9005891,0.000012524937,0.00012986711,0.0000566044,0.00024324302,7.870959e-7,0.00038396553,0.000004465697,0.000012305932,0.086658925],"study_design_scores_gemma":[0.043515135,0.0070009492,0.94800556,0.00009193512,0.00006609109,0.000002199871,0.00009720564,0.000108503555,0.00081758096,0.00006994664,0.00005593037,0.00016895877],"about_ca_topic_score_codex":0.00006895605,"about_ca_topic_score_gemma":0.000036020574,"teacher_disagreement_score":0.08648997,"about_ca_system_score_codex":0.00015557621,"about_ca_system_score_gemma":0.00022513315,"threshold_uncertainty_score":0.9961156},"labels":[],"label_agreement":null},{"id":"W1981322336","doi":"10.1310/b45n-4xhb-53lu-jax9","title":"Selected Topics from the 38th Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and Selected Topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gerontology; Antimicrobial; Library science; Microbiology","score_opus":0.03259492114428208,"score_gpt":0.3132397287706411,"score_spread":0.280644807626359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981322336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958412,0.00036034174,0.00013360813,0.0016502978,0.00034459954,0.0004326187,0.00056261336,0.000007935013,0.0006668104],"genre_scores_gemma":[0.98353744,0.0010749759,0.0005049075,0.004168015,0.0009904982,0.0000031296731,0.00016870297,0.000024961038,0.009527346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744517,0.0007226072,0.00086456724,0.00047773842,0.00023462172,0.0002553013],"domain_scores_gemma":[0.9977534,0.0008027799,0.0006366986,0.00050071947,0.00019623149,0.000110208624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000521117,0.00023787722,0.00058844435,0.0000042100633,0.00014224548,0.000052256324,0.0004125957,0.00019121142,0.0005323885],"category_scores_gemma":[0.0010022921,0.0001367891,0.00018415284,0.00014059011,0.00046029163,0.000013330802,0.00016070645,0.00020565379,7.6903115e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039572635,0.000089653106,0.54544264,0.0000070814813,0.00030785185,9.2999437e-7,0.00044893683,0.00001002988,0.0050657634,0.0000017007715,0.44588217,0.0023475164],"study_design_scores_gemma":[0.0022421605,0.00021648288,0.72858703,0.00016191385,0.00020457723,0.0000030813353,0.00034538866,0.00010164038,0.0023884615,0.000029091538,0.26544732,0.00027284774],"about_ca_topic_score_codex":0.21631907,"about_ca_topic_score_gemma":0.5964903,"teacher_disagreement_score":0.38017124,"about_ca_system_score_codex":0.00008622577,"about_ca_system_score_gemma":0.0014703397,"threshold_uncertainty_score":0.78889954},"labels":[],"label_agreement":null},{"id":"W1982283413","doi":"10.1310/hct1306-301","title":"Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; AIDS Vancouver; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec; Ottawa Hospital; University of Ottawa; Royal Victoria Hospital; McGill University Health Centre; Université de Montréal; Royal Victoria Regional Health Centre","funders":"National Institute on Drug Abuse; Ontario HIV Treatment Network","keywords":"Medicine; Crossover study; Valproic Acid; Clinical study design; Clinical trial; Human immunodeficiency virus (HIV); Randomized controlled trial; Crossover; Research design; Oncology; Pharmacology; Internal medicine; Immunology; Epilepsy; Pathology","score_opus":0.24160368954978242,"score_gpt":0.5034676164749569,"score_spread":0.26186392692517446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982283413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914649,0.003689063,0.00021437406,0.00040445084,0.00015447027,0.0039712037,0.00007091105,0.000007908385,0.000022706905],"genre_scores_gemma":[0.9984493,0.0007645498,0.00022771659,0.0000441087,0.000056198558,0.00019043041,0.000020725713,0.000008328164,0.0002385889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889737,0.009195582,0.0012712809,0.000213717,0.00007891261,0.0002668331],"domain_scores_gemma":[0.9904125,0.008772539,0.00040945652,0.0002711124,0.00007704453,0.000057362966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019150179,0.00012617289,0.0011930779,0.000060906095,0.00010670133,0.000014621179,0.00012513474,0.000105377076,0.00022306689],"category_scores_gemma":[0.003468239,0.00006591606,0.00016455285,0.00009374944,0.00036223698,0.00007069182,0.00009468443,0.00014710092,0.000047239566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51011556,0.0037982988,0.2114118,0.000033205582,0.004814563,0.0000029155433,0.010831976,0.000002368595,0.18144667,0.00024015304,0.010122023,0.06718046],"study_design_scores_gemma":[0.7328468,0.008324944,0.14397785,0.00003341011,0.0005189131,0.0000075111698,0.0034605751,0.0000022304957,0.10883953,0.00023186018,0.001553193,0.00020317866],"about_ca_topic_score_codex":0.00010176552,"about_ca_topic_score_gemma":0.0000046399205,"teacher_disagreement_score":0.22273125,"about_ca_system_score_codex":0.0000075126727,"about_ca_system_score_gemma":0.000055721386,"threshold_uncertainty_score":0.66371083},"labels":[],"label_agreement":null},{"id":"W1985542358","doi":"10.1179/1528433614z.0000000005","title":"<i>Tripterygium wilfordii</i>Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety","year":2015,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Natural Compounds in Disease Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"University of California, San Francisco","keywords":"Medicine; Tripterygium wilfordii; Discontinuation; Tripterygium; Cart; Immune system; Triptolide; Internal medicine; Combination therapy; T cell; Pharmacology; Immunology; Apoptosis","score_opus":0.19265507057799972,"score_gpt":0.43823313118125,"score_spread":0.2455780606032503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985542358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025065,0.0012335016,0.000013981551,0.00071446167,0.0006686408,0.0066676736,0.00009762014,0.0001335818,0.00021987138],"genre_scores_gemma":[0.99723434,0.000023582577,0.0004988788,0.00044526096,0.00024142563,0.00024512844,0.00010607728,0.000077984485,0.0011273214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888718,0.0062659723,0.0024654404,0.0009658805,0.00087621354,0.00055467914],"domain_scores_gemma":[0.98904866,0.008039528,0.00055906345,0.0009795472,0.00043434702,0.00093883846],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01187034,0.0005573266,0.0025500983,0.00038382175,0.00009215416,0.0000673264,0.00024747776,0.00015592614,0.000038710015],"category_scores_gemma":[0.016367018,0.00037913272,0.00023715309,0.0006019753,0.000113558366,0.00021022234,0.00023525103,0.0006174928,0.00012931507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23540476,0.013468175,0.7424525,0.00006361136,0.00077384926,0.00062585535,0.00018322487,0.0000071961254,0.000934388,0.0000041574153,0.0021423663,0.0039399187],"study_design_scores_gemma":[0.0690283,0.032870293,0.8947332,0.00048308258,0.0007876556,0.000008968479,0.000101785525,0.000013715758,0.0003291709,0.000013594868,0.0012734387,0.00035679535],"about_ca_topic_score_codex":0.00004539031,"about_ca_topic_score_gemma":0.000014738734,"teacher_disagreement_score":0.16637644,"about_ca_system_score_codex":0.0004601846,"about_ca_system_score_gemma":0.00042220292,"threshold_uncertainty_score":0.99986607},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W1987974009","doi":"10.1310/hct0804-213","title":"Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Darunavir; Ritonavir; Tolerability; Internal medicine; Regimen; Gastroenterology; Adverse effect; Hepatitis B; Hepatitis C; Alanine transaminase; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.09964593074584223,"score_gpt":0.4511300174849633,"score_spread":0.35148408673912107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987974009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659926,0.00015016623,0.000011057321,0.00016524777,0.0001349852,0.0020873803,0.00011229499,0.000029438863,0.00071016705],"genre_scores_gemma":[0.9970525,0.002067268,0.00047427215,0.0001603692,0.000075480006,0.00004426821,0.000040660983,0.000025906635,0.000059272614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511707,0.0008202757,0.002711309,0.0006078762,0.00034805876,0.0003954277],"domain_scores_gemma":[0.98974675,0.009044151,0.0004372609,0.0003708863,0.00013336897,0.00026758446],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004174826,0.00029031455,0.0022133111,0.00018998313,0.000052507905,0.000014138321,0.00006916893,0.00023536233,0.00012870532],"category_scores_gemma":[0.013892047,0.000194048,0.00012512275,0.00037841283,0.00064457225,0.00010666372,0.000086162436,0.0002521295,0.0000089934665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011229812,0.0029273122,0.952172,0.00004774953,0.00009310612,0.0001316277,0.0009704159,4.5703223e-7,0.00006515359,0.0000132209925,0.000029435196,0.03231972],"study_design_scores_gemma":[0.04303937,0.005613604,0.9493274,0.0004603865,0.00008023443,0.000004773538,0.00010801086,0.000009022347,0.0003625484,0.000019994995,0.0007858204,0.00018885477],"about_ca_topic_score_codex":0.0024649764,"about_ca_topic_score_gemma":0.015942577,"teacher_disagreement_score":0.032130867,"about_ca_system_score_codex":0.00015018212,"about_ca_system_score_gemma":0.00017346963,"threshold_uncertainty_score":0.9944143},"labels":[],"label_agreement":null},{"id":"W1988113084","doi":"10.1310/f45l-fdkk-y48n-n2bt","title":"Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nelfinavir; Medicine; Viral load; Quartile; Protease inhibitor (pharmacology); Internal medicine; Amprenavir; Indinavir; Area under the curve; Gastroenterology; Immunology; Pharmacology; Confidence interval; Virus; Protease; Antiretroviral therapy","score_opus":0.336951842305224,"score_gpt":0.4781353444316747,"score_spread":0.1411835021264507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988113084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053293,0.0003900255,0.0006452006,0.0037633504,0.00025798992,0.0035772582,0.00016785414,0.00006864775,0.00059673283],"genre_scores_gemma":[0.91319025,0.00080898876,0.019104786,0.0007779747,0.00051031914,0.00031078307,0.00013887954,0.00004717306,0.06511086],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958585,0.0010868565,0.0018923521,0.0004718328,0.00035444053,0.000336025],"domain_scores_gemma":[0.99466676,0.0038113166,0.00057157676,0.0004014549,0.0002118639,0.00033702963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00427514,0.00032940056,0.0024223782,0.0001383939,0.00007646216,0.000017244905,0.0001122915,0.00021379294,0.00033727693],"category_scores_gemma":[0.001447701,0.00018327015,0.0005186975,0.00026914207,0.00022396931,0.00008678126,0.000012018148,0.00020468095,0.00005056331],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6643287,0.009367252,0.19015254,0.0002239491,0.0021701327,0.0004001283,0.005136255,0.0000028113968,0.022550253,0.00009161055,0.09745477,0.008121604],"study_design_scores_gemma":[0.2842488,0.028662177,0.011725525,0.0012709391,0.0026788912,0.00009354138,0.0041512153,0.00009196639,0.1344985,0.0002626686,0.5311776,0.0011381536],"about_ca_topic_score_codex":0.0000060402267,"about_ca_topic_score_gemma":0.000009081162,"teacher_disagreement_score":0.43372282,"about_ca_system_score_codex":0.000038342056,"about_ca_system_score_gemma":0.0006483224,"threshold_uncertainty_score":0.74735403},"labels":[],"label_agreement":null},{"id":"W1988473048","doi":"10.1310/feed-6t8u-0bug-6hqh","title":"Randomized Trials Stopped Early for Harm in HIV/AIDS: A Systematic Survey","year":2006,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia; AIDS Vancouver; University of Ottawa","funders":"International AIDS Society","keywords":"Medicine; Data monitoring committee; Interim; Harm; Randomized controlled trial; Adverse effect; Psychological intervention; Clinical trial; Population; Family medicine; Environmental health; Internal medicine; Psychiatry","score_opus":0.9477098910306675,"score_gpt":0.7483044210610479,"score_spread":0.1994054699696196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988473048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019364601,0.92301494,0.0019911027,0.0005671745,0.0027127792,0.06884875,0.001941847,0.00014227773,0.0007617442],"genre_scores_gemma":[0.000017290296,0.9547511,0.003566728,0.00029738242,0.0042870604,0.009917538,0.0014325018,0.0003128209,0.02541761],"study_design_codex":"systematic_review","study_design_gemma":"randomized_trial","domain_scores_codex":[0.5090577,0.3967606,0.083290555,0.003960177,0.004725527,0.0022054475],"domain_scores_gemma":[0.02419385,0.9560202,0.013855513,0.0031241113,0.0017869109,0.0010194565],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"category_scores_codex":[0.84551746,0.0014190885,0.09732977,0.0011437926,0.00012255013,0.0003070099,0.0016142987,0.006871051,0.00038263257],"category_scores_gemma":[0.9829137,0.00084556174,0.023132462,0.0013166312,0.0011074343,0.000097292046,0.0004077707,0.008336134,0.001187852],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18522209,0.0020636725,0.00010392584,0.7307497,0.0062744743,0.0001290393,0.00003545124,4.3499406e-7,1.5834775e-7,0.0045992467,0.015940672,0.054881077],"study_design_scores_gemma":[0.46648353,0.0010063021,0.000016602176,0.37330997,0.021568483,0.000011463937,0.000013438845,0.00003080711,3.3333956e-7,0.00888924,0.12779826,0.00087154884],"about_ca_topic_score_codex":0.00017756094,"about_ca_topic_score_gemma":0.00014060576,"teacher_disagreement_score":0.55925953,"about_ca_system_score_codex":0.00040611147,"about_ca_system_score_gemma":0.0060012466,"threshold_uncertainty_score":0.99985594},"labels":[],"label_agreement":null},{"id":"W1990715538","doi":"10.1310/hct0901-43","title":"Systematic Review and Meta–Analysis of the Diagnostic Accuracy of Fibrosis Marker Panels in Patients with HIV/Hepatitis C Coinfection","year":2008,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Liver Foundation","keywords":"Medicine; Cirrhosis; Receiver operating characteristic; Fibrosis; Internal medicine; Coinfection; Hepatitis C; Liver biopsy; Hepatitis C virus; Gastroenterology; Meta-analysis; Odds ratio; Biopsy; Human immunodeficiency virus (HIV); Pathology; Immunology; Virus","score_opus":0.28699899790588745,"score_gpt":0.49542791165484074,"score_spread":0.20842891374895328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990715538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027902465,0.9853466,0.000013230701,0.00010262478,0.000060068898,0.013017622,0.0010778488,0.000011297017,0.000091691676],"genre_scores_gemma":[0.00056023273,0.99778897,0.000069244285,0.000130429,0.000035417692,0.00095006195,0.00022952801,0.0000508586,0.00018523276],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9759882,0.014137563,0.007861874,0.00060735276,0.0011186921,0.00028629514],"domain_scores_gemma":[0.9135837,0.07896367,0.0051966393,0.0015267283,0.00051778974,0.00021149438],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010706874,0.00049166556,0.024389278,0.00053831725,0.000042124877,0.0000149534535,0.0003162689,0.0004390744,0.0005634126],"category_scores_gemma":[0.2176215,0.00023483139,0.004780133,0.0023062069,0.00033809317,0.00007939733,0.00017384048,0.00070057675,0.000028607452],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006574933,0.0005412851,0.057428323,0.8309356,0.0951153,0.000010695808,0.0000144373125,4.7657724e-7,1.23745005e-8,0.0000039007605,0.0008006397,0.015083562],"study_design_scores_gemma":[0.0013683242,0.0003300843,0.03243883,0.22770478,0.730561,0.000003874175,8.591832e-7,0.0000044611315,1.9797838e-7,0.0000018620634,0.0073731113,0.00021257397],"about_ca_topic_score_codex":0.00020520063,"about_ca_topic_score_gemma":0.00005434447,"teacher_disagreement_score":0.6354458,"about_ca_system_score_codex":0.00009979455,"about_ca_system_score_gemma":0.00046826844,"threshold_uncertainty_score":0.99009466},"labels":[],"label_agreement":null},{"id":"W1991408322","doi":"10.1310/hct0806-400","title":"Effectiveness and Tolerability of Oral Administration of Low-Dose Salmon Oil to HIV Patients with HAART-Associated Dyslipidemia","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Abbott (Canada); Université Laval; Centre hospitalier de l'Université Laval; Maple Leaf Medical Clinic","funders":"Abbott Canada; Abbott Laboratories","keywords":"Medicine; Dyslipidemia; Tolerability; Fish oil; Adverse effect; Concomitant; Internal medicine; Triglyceride; Gastroenterology; Cholesterol; Fish <Actinopterygii>; Fishery; Disease","score_opus":0.09556612374720039,"score_gpt":0.4636352470363737,"score_spread":0.3680691232891733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991408322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976083,0.000029625458,0.00030176403,0.0003815429,0.000112029746,0.0010905415,0.0001132526,0.00002438042,0.00033854457],"genre_scores_gemma":[0.9985004,0.000014011067,0.0011149496,0.00007809058,0.000037876107,0.000030992258,0.00013361657,0.000014274365,0.00007580448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603784,0.0009939045,0.002121163,0.00035767307,0.00027952966,0.00020989237],"domain_scores_gemma":[0.9924266,0.0056051514,0.00080565776,0.0003613296,0.0004704903,0.00033080063],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00887163,0.00015159903,0.001351862,0.00008216318,0.00005319833,0.0000045471975,0.000054088763,0.00024073337,0.000031248015],"category_scores_gemma":[0.009462069,0.00010863953,0.00014515757,0.00028561708,0.0001185623,0.000044515084,0.000023921371,0.00019076394,0.000016129432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011612115,0.003160887,0.95619565,0.00027150896,0.00019295412,0.0000035174398,0.00005502271,0.0000034909294,0.00015552645,0.000051377483,0.00014202022,0.028155904],"study_design_scores_gemma":[0.0127036525,0.0030942606,0.982274,0.0007131814,0.00025946053,6.8588776e-7,0.000011517603,0.000024658666,0.00064202386,0.000064540836,0.00012780503,0.000084219726],"about_ca_topic_score_codex":0.000026768505,"about_ca_topic_score_gemma":0.000025264091,"teacher_disagreement_score":0.028071685,"about_ca_system_score_codex":0.0000817883,"about_ca_system_score_gemma":0.0002060261,"threshold_uncertainty_score":0.99888164},"labels":[],"label_agreement":null},{"id":"W1992656981","doi":"10.1310/hct1006-413","title":"A Systematic Review of the Quality of Trials Evaluating Biomedical HIV Prevention Interventions Shows That Many Lack Power","year":2009,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Public Health Ontario; Hospital for Sick Children; Institute for Clinical Evaluative Sciences; McGill University; Mount Sinai Hospital; SickKids Foundation; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Psychological intervention; Randomized controlled trial; Clinical trial; Systematic review; Human immunodeficiency virus (HIV); Intensive care medicine; MEDLINE; Family medicine; Internal medicine; Psychiatry","score_opus":0.9678022509413752,"score_gpt":0.8037718717577813,"score_spread":0.16403037918359387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992656981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005332388,0.97134334,0.00065058365,0.0028842776,0.0014179755,0.021951998,0.00056336116,0.000043681815,0.0011394502],"genre_scores_gemma":[0.000015549398,0.9828736,0.0012297425,0.00055699964,0.0007166053,0.0006829643,0.00021380738,0.00007771249,0.013632984],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.6736715,0.23721848,0.07735446,0.001957883,0.008912222,0.0008854466],"domain_scores_gemma":[0.09455933,0.8319252,0.06112724,0.007870104,0.003460541,0.0010575934],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad","research_integrity"],"category_scores_codex":[0.6828751,0.00074223016,0.036662024,0.00033517907,0.00008607668,0.000044179993,0.0019179841,0.0027880196,0.0024703566],"category_scores_gemma":[0.9398291,0.00037792043,0.030368473,0.0011312994,0.0012616992,0.000073592484,0.00077429955,0.0054135947,0.00021231685],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019214978,0.0017229076,0.000010404173,0.9297968,0.00250789,0.0000038148874,0.000014167668,1.4404926e-8,0.0000013122935,0.0016271201,0.006195877,0.057927515],"study_design_scores_gemma":[0.0031716714,0.0012180256,0.000026312653,0.9425944,0.02862231,0.0000137324205,0.000024836489,0.0000037974876,0.0000010570758,0.0049467175,0.019107746,0.0002693572],"about_ca_topic_score_codex":0.000006633821,"about_ca_topic_score_gemma":0.000006329077,"teacher_disagreement_score":0.5947067,"about_ca_system_score_codex":0.00027226732,"about_ca_system_score_gemma":0.005252168,"threshold_uncertainty_score":0.99986726},"labels":[],"label_agreement":null},{"id":"W1996104688","doi":"10.1310/hct0805-259","title":"Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; GDI Integrated Facility Services (Canada); St. Michael's Hospital; Western University; McMaster University Medical Centre; University of British Columbia; Abbott (Canada); University of Toronto","funders":"Abbott Canada; Gilead Sciences","keywords":"Medicine; Regimen; Lopinavir; Lamivudine; Ritonavir; Adverse effect; Discontinuation; Randomized controlled trial; Internal medicine; Lopinavir/ritonavir; Clinical endpoint; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Virus; Antiretroviral therapy; Hepatitis B virus","score_opus":0.11908434106831939,"score_gpt":0.38938264742990997,"score_spread":0.2702983063615906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996104688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97013974,0.00009575516,0.000037044356,0.009058801,0.00082682614,0.011107956,0.000028091747,0.00009283501,0.008612956],"genre_scores_gemma":[0.9951258,0.00050087116,0.00046563678,0.00069984724,0.0005976619,0.00052633864,0.00012956765,0.0000510509,0.0019032258],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98818046,0.0048244847,0.0046930667,0.0008565412,0.00078401004,0.0006614622],"domain_scores_gemma":[0.89157104,0.10526552,0.0019362173,0.00071908615,0.00021015514,0.00029800317],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03296312,0.00060974807,0.0059944717,0.00030368337,0.00019564797,0.000048523845,0.00026588503,0.0005245082,0.00013484748],"category_scores_gemma":[0.06607142,0.00031464285,0.0011171038,0.00033428325,0.0005098413,0.0000809005,0.000117101496,0.00078677695,0.000051957864],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98279303,0.0022420208,0.008449757,0.00001652922,0.0012819332,0.0000714828,0.0005753332,0.000005379403,0.000048820555,0.001096385,0.0013186805,0.0021006442],"study_design_scores_gemma":[0.9794906,0.005935324,0.009272313,0.0007025262,0.0007242008,0.0000013964907,0.00022196464,0.00014859086,0.0002467416,0.00026935563,0.002678955,0.00030804635],"about_ca_topic_score_codex":0.000017095848,"about_ca_topic_score_gemma":0.0000317694,"teacher_disagreement_score":0.10044104,"about_ca_system_score_codex":0.00015319746,"about_ca_system_score_gemma":0.00021346725,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W1999280643","doi":"10.1310/hct0705-251","title":"Infection Rates in HIV-HCV Patients Treated with Interferon Are Similar to Those in HCV Mono-Infection and Not Related to Neutropenia","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Human immunodeficiency virus (HIV); Interferon; Infection rate; Internal medicine; Immunology; Ribavirin; Hepatitis C virus; Virus; Surgery; Chemotherapy","score_opus":0.17411955403498594,"score_gpt":0.47486931815223443,"score_spread":0.3007497641172485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999280643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943491,0.000017816797,0.00005096856,0.0015490304,0.00015160191,0.0027994062,0.00003611602,0.00007402737,0.00097188586],"genre_scores_gemma":[0.9980794,0.00021655615,0.00019172813,0.0004150972,0.00015211309,0.0001787038,0.000097841315,0.000045868095,0.0006226493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946014,0.0020899738,0.0019035747,0.00065231806,0.0003486989,0.00040401073],"domain_scores_gemma":[0.9973239,0.0015450825,0.00026940458,0.00033174828,0.00021065304,0.0003192322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043096514,0.00025582337,0.0012416276,0.0005968647,0.000048167447,0.000059507907,0.000066387256,0.00033402845,0.00011063259],"category_scores_gemma":[0.008807352,0.00019710815,0.000116020674,0.0009474856,0.000064465414,0.00016235064,0.00009097324,0.0006114709,0.0002869023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007484408,0.0006400985,0.97131926,0.000032251228,0.000036753998,0.00005437403,0.0000651471,0.00015366197,0.0004929111,0.0000066718926,0.0021923531,0.017522128],"study_design_scores_gemma":[0.012892273,0.00335992,0.976871,0.0007091865,0.000054530516,0.0000011704275,0.0000074155487,0.0003948662,0.0013846178,0.000028480874,0.0040925364,0.00020399482],"about_ca_topic_score_codex":0.0031249146,"about_ca_topic_score_gemma":0.005284388,"teacher_disagreement_score":0.017318133,"about_ca_system_score_codex":0.00025187535,"about_ca_system_score_gemma":0.000079976926,"threshold_uncertainty_score":0.9995419},"labels":[],"label_agreement":null},{"id":"W2003082239","doi":"10.1310/hct1503-116","title":"Factors Associated With Study Attrition Among HIV-Infected Risky Drinkers in St. Petersburg, Russia","year":2014,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV, Drug Use, Sexual Risk","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; McMaster University","keywords":"Medicine; Attrition; Binge drinking; Logistic regression; Proportional hazards model; Demography; Hazard ratio; Human immunodeficiency virus (HIV); Psychiatry; Gerontology; Internal medicine; Environmental health; Confidence interval; Family medicine; Poison control; Suicide prevention","score_opus":0.33629799678827704,"score_gpt":0.47530698100558566,"score_spread":0.13900898421730862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003082239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448067,0.000013701521,0.00018504461,0.00039649682,0.00048103006,0.0027104309,0.00008729477,0.00032103772,0.0013243123],"genre_scores_gemma":[0.99785995,0.000019265459,0.00007766329,0.00015102931,0.0005688272,0.00007656009,0.00038003855,0.00008956224,0.0007770969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98744404,0.007117403,0.0030168488,0.000912538,0.0008741845,0.0006350001],"domain_scores_gemma":[0.98158866,0.015621883,0.0011900646,0.00080891827,0.00020231218,0.00058818574],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01669634,0.00048004382,0.0028800948,0.0003376686,0.00010782252,0.00006552441,0.00024208838,0.00051873486,0.0003647825],"category_scores_gemma":[0.06529529,0.00033298513,0.00045452153,0.0007424282,0.00026873781,0.00018061051,0.00008243043,0.001121263,0.00015474566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010695199,0.0027907474,0.99012315,0.000019487032,0.0004448213,0.00004834496,0.00094303064,0.000019210504,0.00006436728,0.000012404136,0.003058755,0.0014061551],"study_design_scores_gemma":[0.028504713,0.003137604,0.9622224,0.0003919602,0.00081526715,8.1205764e-7,0.0035006546,0.00034154378,0.000062048355,0.000057234243,0.0005844128,0.00038134836],"about_ca_topic_score_codex":0.000121003555,"about_ca_topic_score_gemma":0.00052429386,"teacher_disagreement_score":0.048598945,"about_ca_system_score_codex":0.00020100191,"about_ca_system_score_gemma":0.00016025288,"threshold_uncertainty_score":0.9999122},"labels":[],"label_agreement":null},{"id":"W2003655730","doi":"10.1310/b6t0-n98j-1j3m-eqpk","title":"Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens","year":2002,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Abacavir; Mycophenolate; Internal medicine; Salvage therapy; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Immunology; Antiretroviral therapy; Chemotherapy; Transplantation","score_opus":0.2900278795689513,"score_gpt":0.4613258626269102,"score_spread":0.1712979830579589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003655730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514665,0.0014100936,0.00003684948,0.010528163,0.00058510527,0.0018575605,0.000098094766,0.00006531607,0.010272192],"genre_scores_gemma":[0.94610083,0.0049482114,0.004584917,0.00014368277,0.00049683877,0.00006431253,0.000040904157,0.000037965547,0.043582328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497813,0.001453886,0.002612948,0.00037001356,0.00032116598,0.00026385227],"domain_scores_gemma":[0.9932697,0.0050099976,0.00071357924,0.00069011445,0.00013230479,0.00018433394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043551037,0.00026052727,0.001673177,0.00006714511,0.00014132613,0.000017591938,0.00009066304,0.00016996455,0.00088072807],"category_scores_gemma":[0.0034844403,0.00013950779,0.00064462825,0.00019708693,0.0002831238,0.00009555439,0.000049847018,0.00016946926,0.00016156754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018611,0.024349289,0.19903322,0.0006953318,0.01868129,0.024101483,0.02125119,0.00011780964,0.004339277,0.0045762933,0.12179425,0.5624496],"study_design_scores_gemma":[0.10157844,0.006198164,0.008705049,0.002596708,0.008143618,0.0064240275,0.0050461,0.0010711682,0.048025522,0.0009927561,0.80989796,0.0013205049],"about_ca_topic_score_codex":0.000030702282,"about_ca_topic_score_gemma":0.000009701094,"teacher_disagreement_score":0.6881037,"about_ca_system_score_codex":0.00007460237,"about_ca_system_score_gemma":0.0001273807,"threshold_uncertainty_score":0.9643355},"labels":[],"label_agreement":null},{"id":"W2006674154","doi":"10.1310/hct1302-111","title":"Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Division of Chemistry","keywords":"Medicine; Baseline (sea); Immunology; Internal medicine","score_opus":0.2652432090282322,"score_gpt":0.4965311565393695,"score_spread":0.23128794751113735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006674154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958458,0.0005766154,0.0000066182283,0.0015957266,0.00016952236,0.0015631466,0.00004805967,0.000029266419,0.00016524793],"genre_scores_gemma":[0.9972917,0.0013155461,0.00020395088,0.00043740662,0.00026403513,0.00008513729,0.000031842028,0.000012268038,0.00035812554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913455,0.0057931393,0.0018866397,0.00032594756,0.00028363933,0.0003651234],"domain_scores_gemma":[0.9798569,0.018902153,0.0005618391,0.0004899639,0.000054312557,0.0001348464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028034134,0.00026886418,0.0015577096,0.00021874388,0.000064133834,0.000013520975,0.00015546863,0.00025119516,0.0001952599],"category_scores_gemma":[0.024602104,0.00012516839,0.00040859787,0.00027805206,0.00023572535,0.00004550075,0.00007138513,0.00045224032,0.00005885043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008962499,0.0061510107,0.97526276,0.000007590614,0.0004093967,0.00006465708,0.00041031334,1.6515821e-7,0.00018081076,0.000029393672,0.00068097573,0.007840453],"study_design_scores_gemma":[0.0072306492,0.0049698884,0.98616666,0.000036155943,0.00039930354,0.000016091433,0.00027772173,0.000007716562,0.000021395219,0.00005630957,0.0007006392,0.00011746847],"about_ca_topic_score_codex":0.0000060405464,"about_ca_topic_score_gemma":0.0000017984477,"teacher_disagreement_score":0.013109013,"about_ca_system_score_codex":0.000027683724,"about_ca_system_score_gemma":0.00007275699,"threshold_uncertainty_score":0.9836141},"labels":[],"label_agreement":null},{"id":"W2013976388","doi":"10.1310/p52n-kxjh-1945-ux7x","title":"The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom","year":2000,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Life expectancy; Nucleoside analogue; Quality-adjusted life year; Cost effectiveness; Clinical trial; Quality of life (healthcare); Observational study; Population; Antiretroviral therapy; Human immunodeficiency virus (HIV); Intensive care medicine; Viral load; Internal medicine; Nucleoside; Family medicine; Environmental health; Risk analysis (engineering)","score_opus":0.2806454061765764,"score_gpt":0.465997805989622,"score_spread":0.18535239981304558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013976388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072987,0.00044210756,0.000006662573,0.003976643,0.00013363533,0.0038923891,0.00004424439,0.000013304623,0.0007611214],"genre_scores_gemma":[0.99360454,0.0046186205,0.00006796367,0.00024709862,0.0001422571,0.0002813815,0.00013431536,0.0000180786,0.0008857493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892146,0.007896333,0.0018406393,0.00031486677,0.00042331123,0.00031026237],"domain_scores_gemma":[0.9788746,0.019892478,0.00041626234,0.0006974389,0.00006244408,0.000056753106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014534367,0.00025174892,0.0013561683,0.0001577928,0.00009759766,0.000022495298,0.00030976528,0.00015665924,0.00009215896],"category_scores_gemma":[0.0014507008,0.000099178986,0.00054209225,0.0008639056,0.00031918523,0.00003559084,0.000010645527,0.00022875919,0.000028990771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026208427,0.012420989,0.82525706,0.000052612082,0.00130147,0.00024952128,0.0052293255,0.00004462542,0.00035238947,0.0023360117,0.0038462155,0.12270133],"study_design_scores_gemma":[0.053265736,0.0043811523,0.7888859,0.00037979652,0.00042177062,0.000012886197,0.0008935692,0.00012826994,0.0019644937,0.0005186717,0.14893328,0.00021448598],"about_ca_topic_score_codex":0.0002491285,"about_ca_topic_score_gemma":0.00006992878,"teacher_disagreement_score":0.14508706,"about_ca_system_score_codex":0.00008777246,"about_ca_system_score_gemma":0.00016005454,"threshold_uncertainty_score":0.50373507},"labels":[],"label_agreement":null},{"id":"W2015215132","doi":"10.1310/hct1001-63","title":"HIV Essentials By Paul E. Sax, Calvin J. Cohen, and Daniel R. Kuritzkes. Jones &amp; Bartlett Publishers, 2008, 200 pp","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Classics; Family medicine; Art","score_opus":0.1527906471076678,"score_gpt":0.46098054972833885,"score_spread":0.30818990262067103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015215132","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33448955,0.070838906,0.004610085,0.51551044,0.005570014,0.013481736,0.0027253015,0.0014539174,0.051320035],"genre_scores_gemma":[0.5610707,0.041641716,0.01863281,0.0453798,0.008601489,0.0006204608,0.008786954,0.00037289478,0.3148932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939028,0.0012128622,0.0029382287,0.00087650964,0.00045617652,0.0006134202],"domain_scores_gemma":[0.99377275,0.0033464024,0.00068109366,0.0009946804,0.00024944017,0.00095564564],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005409958,0.0003736867,0.0018917309,0.00012286576,0.00027203173,0.00017028229,0.000204436,0.0005880783,0.0013089807],"category_scores_gemma":[0.008085324,0.0002926823,0.0004073747,0.00035686104,0.00020700917,0.00026739892,0.000055388497,0.00062425784,0.0010975243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003433816,0.0011910413,0.011848603,0.00003444354,0.00020589774,0.00002894452,0.000036233054,5.816222e-7,0.00034079238,0.00017901631,0.9778427,0.007948349],"study_design_scores_gemma":[0.010898971,0.00043638877,0.020026483,0.00022501193,0.0006542772,0.00005036267,0.000032690794,0.000051971263,0.00007273183,0.0012009433,0.9660337,0.00031645494],"about_ca_topic_score_codex":0.000050933362,"about_ca_topic_score_gemma":0.000009350326,"teacher_disagreement_score":0.47013065,"about_ca_system_score_codex":0.0000630129,"about_ca_system_score_gemma":0.00026653666,"threshold_uncertainty_score":0.99995255},"labels":[],"label_agreement":null},{"id":"W2020067315","doi":"10.1310/95ve-a6kj-wrq0-1f8y","title":"Mild to Moderate Symptoms Do Not Correlate with Lactate Levels in HIV-Positive Patients on Nucleoside Reverse Transcriptase Inhibitors","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Human immunodeficiency virus (HIV); Nucleoside; Reverse-transcriptase inhibitor; Pharmacology; Internal medicine; Virology; Antiretroviral therapy; Viral load; RNA; Biochemistry","score_opus":0.11369221170588129,"score_gpt":0.4102275988494202,"score_spread":0.29653538714353894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020067315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867869,0.000041160165,0.00023996677,0.005707804,0.0003993357,0.0031129105,0.00079847756,0.0000842977,0.0028291368],"genre_scores_gemma":[0.9927009,0.000043454515,0.00116797,0.0035893896,0.00022886036,0.0001599163,0.00030309122,0.000060732516,0.0017457118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994904,0.00094770995,0.0024233956,0.00077715167,0.00043897406,0.0005087866],"domain_scores_gemma":[0.99657476,0.0017207356,0.00046428308,0.0005287109,0.00020926802,0.0005022174],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020187665,0.0003603457,0.0013796841,0.00026454212,0.00015153183,0.000035804926,0.000108482236,0.00031316534,0.00011061027],"category_scores_gemma":[0.0008583135,0.00026491817,0.00030051905,0.00044915613,0.00009277713,0.00010245817,0.000022971595,0.0006233592,0.001148432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09257452,0.026880533,0.6962469,0.00026192667,0.0014356871,0.0011072973,0.00210377,0.004136108,0.0006456007,0.0034483734,0.124418996,0.04674025],"study_design_scores_gemma":[0.054487947,0.0049846717,0.926831,0.0028126696,0.00070013053,0.000008597691,0.000045061286,0.00065322313,0.0006709229,0.00037182833,0.007839524,0.0005944356],"about_ca_topic_score_codex":0.0002124271,"about_ca_topic_score_gemma":0.000037301223,"teacher_disagreement_score":0.23058406,"about_ca_system_score_codex":0.00020696486,"about_ca_system_score_gemma":0.00017710445,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W2023680960","doi":"10.1310/hct1106-340","title":"Effect of Gender and Calendar Year on Time to and Duration of Virologic Suppression Among Antiretroviral-Naïve HIV-Infected Individuals Initiating Combination Antiretroviral Therapy","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Maple Leaf Medical Clinic; Ontario HIV Treatment Network; St. Michael's Hospital; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Health Canada; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Interquartile range; Hazard ratio; Regimen; Proportional hazards model; Viral load; Antiretroviral therapy; Cohort; Internal medicine; Human immunodeficiency virus (HIV); Cohort study; Confidence interval; Immunology","score_opus":0.09042930505775788,"score_gpt":0.447746397133398,"score_spread":0.3573170920756401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023680960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971664,0.0000391067,0.00009778857,0.00016668883,0.00008812892,0.0013264987,0.00027868716,0.00003179561,0.00080492627],"genre_scores_gemma":[0.9987797,0.000114517556,0.00022890167,0.000052692416,0.0001597408,0.000023032631,0.00013551058,0.000018724599,0.00048717987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945293,0.003037489,0.0014672334,0.00034042398,0.00040885288,0.00021671885],"domain_scores_gemma":[0.9933864,0.005371158,0.00059139525,0.00026705654,0.00015470288,0.00022932017],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011363241,0.00017348769,0.0010404451,0.00027488355,0.00007491502,0.00002278006,0.000085970794,0.00030804923,0.0005003257],"category_scores_gemma":[0.029918658,0.00011967228,0.00026674324,0.00019767937,0.00028937354,0.00014757617,0.00007563962,0.0005204795,0.00005531188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00228346,0.0005257609,0.67687935,0.0001522548,0.0001479441,0.0000048193515,0.00012172277,3.357101e-7,0.25628704,0.00010162137,0.005411089,0.058084596],"study_design_scores_gemma":[0.013268052,0.050594717,0.8453453,0.00037848591,0.00015988598,0.000004060947,0.00002637541,0.0012106322,0.08850285,0.00011424949,0.0002291462,0.00016620713],"about_ca_topic_score_codex":0.000011247679,"about_ca_topic_score_gemma":6.838584e-7,"teacher_disagreement_score":0.16846597,"about_ca_system_score_codex":0.00000925873,"about_ca_system_score_gemma":0.000042327352,"threshold_uncertainty_score":0.97825277},"labels":[],"label_agreement":null},{"id":"W2023936662","doi":"10.1310/hct1306-357","title":"Physician Attitudes Regarding Pregnancy, Fertility Care, and Assisted Reproductive Technologies for HIV-Infected Individuals and Couples","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Reproductive Health and Technologies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of British Columbia Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Fertility; Medicine; Assisted reproductive technology; Family medicine; Pregnancy; Population; Logistic regression; Reproductive medicine; Reproductive health; Fertility clinic; Gynecology; Infertility; Environmental health","score_opus":0.2701846422825666,"score_gpt":0.4840508541485525,"score_spread":0.21386621186598587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023936662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95075935,0.03828725,0.0002684207,0.004425223,0.0004896603,0.004051219,0.00014414106,0.0010502007,0.0005245225],"genre_scores_gemma":[0.9867221,0.0027905852,0.0092797475,0.00010790132,0.0005488793,0.0003835511,0.000052636708,0.000030792566,0.00008377242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962835,0.0004926407,0.0014096227,0.0010338787,0.00022605754,0.0005543285],"domain_scores_gemma":[0.9935668,0.004258164,0.0006739692,0.0009763713,0.0003524161,0.00017228493],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0066148937,0.00029684883,0.0017630343,0.00015810717,0.00023508555,0.000040371036,0.00012255677,0.0005101487,0.0000034841132],"category_scores_gemma":[0.091150254,0.00021423234,0.00024732965,0.0002676386,0.00087178865,0.00022726432,0.00023013634,0.0004768352,0.0000059650033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074302935,0.00035201368,0.74849015,0.0006778885,0.00026028964,0.0000016241855,0.00012820493,5.9554267e-8,0.0009031668,0.00078235497,0.0010866787,0.24657455],"study_design_scores_gemma":[0.0046155364,0.00090153597,0.96623486,0.00069202314,0.00051846815,0.000012799855,0.0011703285,0.0000033929387,0.010597252,0.002242821,0.01273973,0.0002712344],"about_ca_topic_score_codex":0.0000058898713,"about_ca_topic_score_gemma":0.0000016076873,"teacher_disagreement_score":0.24630332,"about_ca_system_score_codex":0.000054582884,"about_ca_system_score_gemma":0.00010242799,"threshold_uncertainty_score":0.9165054},"labels":[],"label_agreement":null},{"id":"W2034769242","doi":"10.1310/3hhb-59up-93mm-aaxy","title":"HIV Lipodystrophy: A Review","year":2000,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lipodystrophy; Medicine; Stavudine; Diabetes mellitus; Hyperlipidemia; Metabolic syndrome; Antiretroviral therapy; Bioinformatics; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Endocrinology; Viral load; Biology","score_opus":0.5069420519687867,"score_gpt":0.6030165185156607,"score_spread":0.09607446654687402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034769242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.0686485e-7,0.97719026,0.00001544018,0.0021236888,0.0004282148,0.006656687,0.00044156102,0.00015309604,0.012990859],"genre_scores_gemma":[9.2411e-8,0.9750205,0.0010482372,0.0018466361,0.0019212898,0.0008730461,0.0018522947,0.000107061074,0.01733079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9861121,0.0040606544,0.007916921,0.0010073205,0.000408455,0.0004945599],"domain_scores_gemma":[0.98803043,0.006974146,0.0021782094,0.001844195,0.00013830009,0.00083469483],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007558459,0.00065677986,0.012528552,0.00018304978,0.0001280843,0.000022774673,0.00032136514,0.001024567,0.005214755],"category_scores_gemma":[0.0075556673,0.0004170407,0.004358347,0.00059626024,0.000114637405,0.00003352843,0.00005786829,0.0014732053,0.029123677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004177601,0.00047299295,0.0000075768808,0.03481414,0.00061829505,0.000072370145,0.0000011257339,9.092781e-9,1.23999e-9,0.00005282767,0.15729137,0.8066275],"study_design_scores_gemma":[0.00161678,0.00027944575,0.00000718591,0.19570799,0.012222004,0.00012400758,2.7285668e-7,8.9728536e-7,3.4834053e-9,0.000035258476,0.78977954,0.000226621],"about_ca_topic_score_codex":0.0000045038437,"about_ca_topic_score_gemma":2.0424937e-7,"teacher_disagreement_score":0.8064009,"about_ca_system_score_codex":0.00015204912,"about_ca_system_score_gemma":0.0015238426,"threshold_uncertainty_score":0.99982816},"labels":[],"label_agreement":null},{"id":"W2035341996","doi":"10.1310/hct1002-76","title":"Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Clair College","funders":"GlaxoSmithKline","keywords":"Medicine; Abacavir; Lopinavir/ritonavir; Lopinavir; Ritonavir; Interquartile range; Lamivudine; Adverse effect; Viral load; Internal medicine; Gastroenterology; Pharmacology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Virus; Chronic hepatitis","score_opus":0.12890663139448505,"score_gpt":0.4384300801451987,"score_spread":0.30952344875071364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035341996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899601,0.00063804036,0.0002365081,0.0040611913,0.00041666892,0.00225859,0.000055230386,0.00007499415,0.0022986976],"genre_scores_gemma":[0.9936683,0.001291945,0.0015201144,0.00018226352,0.00033034984,0.000039134782,0.00045218473,0.000036220707,0.0024794769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505395,0.0007247885,0.002460884,0.0007188764,0.00061266084,0.00042886304],"domain_scores_gemma":[0.99435216,0.0040450916,0.0006566879,0.0005065827,0.00012804256,0.00031141157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034535662,0.0004287641,0.0021396622,0.0002334677,0.00007793717,0.00002809003,0.00015755133,0.00037539928,0.00014053404],"category_scores_gemma":[0.0019943547,0.00031767343,0.0002942908,0.00042375005,0.0002677383,0.0001872839,0.00007051291,0.0005131379,0.0000568214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12466704,0.011064266,0.4697827,0.00033639953,0.0015639559,0.0008976953,0.0006825441,0.000024980096,0.00081749726,0.0026481724,0.0017761685,0.38573855],"study_design_scores_gemma":[0.11543112,0.003339131,0.87700534,0.0011346382,0.0005795429,0.000018753566,0.000029796505,0.00009591082,0.00040624535,0.00016448252,0.0014368494,0.00035817546],"about_ca_topic_score_codex":0.000017299799,"about_ca_topic_score_gemma":0.000033461132,"teacher_disagreement_score":0.40722263,"about_ca_system_score_codex":0.00019593106,"about_ca_system_score_gemma":0.00029545423,"threshold_uncertainty_score":0.9999275},"labels":[],"label_agreement":null},{"id":"W2037740736","doi":"10.1310/hct1304-179","title":"A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia; Ottawa Hospital; Abbott (Canada); University of Ottawa","funders":"Ontario HIV Treatment Network; Abbott Laboratories","keywords":"Medicine; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Prospective cohort study; Lopinavir/ritonavir; Internal medicine; Viral load; Pharmacology; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.28697042477038737,"score_gpt":0.5185631127525557,"score_spread":0.23159268798216837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037740736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971732,0.00019145204,0.000054889744,0.0032679548,0.0003183443,0.023965476,0.00004483271,0.000034722052,0.00039031735],"genre_scores_gemma":[0.99682885,0.00024682452,0.00038844367,0.00040922282,0.00025540896,0.0010303047,0.000039708233,0.000043496573,0.0007577568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99188465,0.0040684417,0.0024848715,0.00056997535,0.00061018975,0.00038189397],"domain_scores_gemma":[0.9924791,0.0057126437,0.0005431353,0.0007359217,0.0002962397,0.00023300035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013682237,0.0003538952,0.0014135474,0.00011163182,0.00017831288,0.00006125656,0.0004174004,0.00006139306,0.000061721534],"category_scores_gemma":[0.0041062413,0.00018604232,0.0000931865,0.000606697,0.00014950543,0.00011222322,0.0002566243,0.00037963848,0.00008262584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012500225,0.04787905,0.9018008,0.000012272481,0.0007750353,0.0000030707931,0.0062842327,0.0000049298956,0.00013366413,0.000045042278,0.0016566834,0.028904976],"study_design_scores_gemma":[0.09507014,0.0060251486,0.8935567,0.00009046992,0.0008022522,8.198971e-7,0.0011397197,0.00007779877,0.00011834372,0.000037181282,0.002882065,0.00019932026],"about_ca_topic_score_codex":0.000069046306,"about_ca_topic_score_gemma":0.000053136693,"teacher_disagreement_score":0.08256991,"about_ca_system_score_codex":0.00013146613,"about_ca_system_score_gemma":0.00016125668,"threshold_uncertainty_score":0.7586586},"labels":[],"label_agreement":null},{"id":"W2048157797","doi":"10.1310/hct1202-89","title":"Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Sunnybrook Health Science Centre; St. Michael's Hospital; Women's College Hospital; Ontario HIV Treatment Network; Canadians Living with HIV; Health Sciences Centre; University Health Network; University of Toronto","funders":"Division of Undergraduate Education","keywords":"Lipodystrophy; Medicine; Lipoatrophy; Multicenter AIDS Cohort Study; Internal medicine; Cross-sectional study; Logistic regression; Ethnic group; Cohort; Prospective cohort study; Univariate analysis; Multivariate analysis; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Pathology; Viral load","score_opus":0.3563934803590323,"score_gpt":0.43659283879343025,"score_spread":0.08019935843439796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048157797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968013,0.00030833567,0.000018629911,0.00019224618,0.00011617557,0.00077152875,0.00006286966,0.00000765447,0.0017212449],"genre_scores_gemma":[0.99840873,0.0003050469,0.00080806686,0.0002587536,0.0000416915,0.000028975699,0.000029507506,0.000009624171,0.000109616325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967022,0.0008772385,0.0016418914,0.0003267936,0.00021127705,0.00024061614],"domain_scores_gemma":[0.9972387,0.0017170674,0.0005973404,0.00022793796,0.000060346738,0.00015861241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021387688,0.0001508272,0.0011516798,0.00012427387,0.000038895985,0.0000052644887,0.00008554952,0.0001914662,0.00028751884],"category_scores_gemma":[0.0010018006,0.00011078666,0.00009925863,0.00017294611,0.00010803457,0.000042302847,0.000032112894,0.0004709795,0.0000040189334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042779584,0.0005432985,0.99224645,0.000014881406,0.00010981962,0.000024406056,0.0010971128,1.6678632e-7,0.000023129875,0.00015225762,0.00009924993,0.0052614445],"study_design_scores_gemma":[0.0058062887,0.00081424,0.9924983,0.00017623234,0.00005961029,0.0000025964869,0.00008627707,0.000017418428,0.00005068683,0.00035035866,0.000051395076,0.000086594526],"about_ca_topic_score_codex":0.7609767,"about_ca_topic_score_gemma":0.553352,"teacher_disagreement_score":0.20762467,"about_ca_system_score_codex":0.00013826472,"about_ca_system_score_gemma":0.0009085512,"threshold_uncertainty_score":0.45479816},"labels":[],"label_agreement":null},{"id":"W2048476931","doi":"10.1310/cwd3-dr4k-7ee0-7abl","title":"The Efficacy of Calcium Carbonate in the Treatment of Protease Inhibitor-Induced Persistent Diarrhea in HIV-Infected Patients","year":2004,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Pharmacists Association; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Diarrhea; Internal medicine; Visual analogue scale; Calcium carbonate; Calcium; Nelfinavir; Prospective cohort study; Gastroenterology; Human immunodeficiency virus (HIV); Surgery; Immunology; Antiretroviral therapy; Viral load","score_opus":0.17971267512180408,"score_gpt":0.4497504274225439,"score_spread":0.2700377523007398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048476931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908557,0.00029371772,0.0000025940321,0.0033959548,0.0001808715,0.0047849435,0.00004841592,0.000013129536,0.00042467008],"genre_scores_gemma":[0.9989337,0.0003366877,0.000072058836,0.000073476556,0.0001106541,0.00034200258,0.00006715286,0.000015003602,0.00004926506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511814,0.0014729185,0.002475055,0.00031160132,0.00033581868,0.00028649415],"domain_scores_gemma":[0.9937483,0.0046618925,0.0006473747,0.000641962,0.00014976363,0.00015069969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027558748,0.0001888224,0.0010218002,0.00011792629,0.00008030543,0.00000734426,0.00013350906,0.00019159121,0.000009790432],"category_scores_gemma":[0.0042161928,0.000094122144,0.00053058803,0.00043174793,0.00012706617,0.00002207956,0.000018367413,0.00025036887,0.000028272352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070889625,0.042586714,0.912806,0.000119209726,0.0005814629,0.00005073749,0.0035258706,0.00014556806,0.0003067563,0.000539182,0.00018071139,0.032068823],"study_design_scores_gemma":[0.05450179,0.0053075934,0.93711114,0.00047932687,0.00038097755,0.000002035794,0.00014557212,0.000081864615,0.00063914305,0.00014087789,0.0010954805,0.00011416925],"about_ca_topic_score_codex":0.0004172958,"about_ca_topic_score_gemma":0.00005549621,"teacher_disagreement_score":0.047412828,"about_ca_system_score_codex":0.0002590919,"about_ca_system_score_gemma":0.00037158027,"threshold_uncertainty_score":0.5047481},"labels":[],"label_agreement":null},{"id":"W2050657418","doi":"10.1310/hct1101-39","title":"A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy","year":2010,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"National Center for Research Resources; U.S. Public Health Service; National Institutes of Health; Amgen; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Medical Research Council; ACT Government; Bristol-Myers Squibb; GlaxoSmithKline; National Health and Medical Research Council","keywords":"Pioglitazone; Rosiglitazone; Medicine; Placebo; Thiazolidinedione; Stavudine; Internal medicine; Lipoatrophy; Body mass index; Zidovudine; Urology; Endocrinology; Gastroenterology; Pharmacology; Diabetes mellitus; Human immunodeficiency virus (HIV); Antiretroviral therapy; Type 2 diabetes; Viral load; Insulin; Immunology; Pathology","score_opus":0.6418827890290362,"score_gpt":0.5873134464127776,"score_spread":0.054569342616258565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050657418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037757265,0.97200435,0.0005441769,0.0012163627,0.000529751,0.020645952,0.004579634,0.000048161422,0.00039385885],"genre_scores_gemma":[0.00011148532,0.98611885,0.0035920895,0.00016024444,0.0011015768,0.004926178,0.001998798,0.00010242278,0.0018883777],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.963353,0.011111046,0.02334133,0.0010337015,0.00072162406,0.00043934287],"domain_scores_gemma":[0.82548386,0.14985608,0.020638091,0.0023999836,0.0010834329,0.00053853815],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.07327667,0.00088092807,0.08057743,0.0013608909,0.00010652979,0.000020156493,0.0004722257,0.0019259253,0.0022067332],"category_scores_gemma":[0.06910448,0.00044882024,0.06134137,0.0013830399,0.00020745741,0.00003880534,0.000042981657,0.0010246914,0.00009603095],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013927046,0.002635574,0.00001399275,0.003156701,0.78476214,0.0000035686323,0.000030163188,0.0000035703706,0.0000037463647,0.00048244043,0.0028189626,0.1921621],"study_design_scores_gemma":[0.02954615,0.0007762414,0.000003664168,0.00055562385,0.5758184,0.0000019928289,0.0000032115995,0.000033710312,0.000002780113,0.00014108578,0.39294505,0.00017208971],"about_ca_topic_score_codex":0.000013436761,"about_ca_topic_score_gemma":0.000003339547,"teacher_disagreement_score":0.3901261,"about_ca_system_score_codex":0.00004845673,"about_ca_system_score_gemma":0.0014948642,"threshold_uncertainty_score":0.99979633},"labels":[],"label_agreement":null},{"id":"W2050892293","doi":"10.1310/hct1203-151","title":"Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-Naïve HIV-lnfected Patients","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute; Sunnybrook Health Science Centre; McGill University; Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada); Maple Leaf Medical Clinic; Université de Montréal","funders":"","keywords":"Medicine; Ritonavir; Discontinuation; Atazanavir; Viral load; Regimen; Internal medicine; Human immunodeficiency virus (HIV); Gastroenterology; Antiretroviral therapy; Immunology","score_opus":0.1576212044445199,"score_gpt":0.40258714999977185,"score_spread":0.24496594555525195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050892293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912225,0.00015246961,0.00004720556,0.0010262231,0.00018142335,0.004921986,0.00018466287,0.00013194937,0.002131606],"genre_scores_gemma":[0.9938053,0.00038807333,0.00240624,0.0000868304,0.00013451664,0.0006119819,0.00069869176,0.000064186774,0.0018041917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99357575,0.0025588032,0.0018844331,0.0010796905,0.00037374045,0.0005275997],"domain_scores_gemma":[0.99344754,0.004753808,0.00045767846,0.0007164181,0.00014163725,0.00048293304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002563819,0.0006268145,0.0025186583,0.00019848466,0.00012483144,0.000026515387,0.000096799515,0.00031983972,0.00025500535],"category_scores_gemma":[0.0014524745,0.0003769034,0.0004465329,0.00032848166,0.0003098659,0.00012717153,0.000045479454,0.00020032344,0.0001853838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019890664,0.008762817,0.94173783,0.000060681858,0.00089253223,0.000298561,0.0002835587,8.188962e-7,0.000021387477,0.00006363658,0.00017493697,0.027812552],"study_design_scores_gemma":[0.08619694,0.0069812597,0.8978273,0.0004190723,0.0011866135,0.0000121065295,0.000043349013,0.000035421377,0.0014870287,0.00013201145,0.0052799517,0.00039890406],"about_ca_topic_score_codex":0.00020601007,"about_ca_topic_score_gemma":0.00015734685,"teacher_disagreement_score":0.06630627,"about_ca_system_score_codex":0.0006662475,"about_ca_system_score_gemma":0.00048491705,"threshold_uncertainty_score":0.9998683},"labels":[],"label_agreement":null},{"id":"W2058157173","doi":"10.1310/a9b9-rqd7-u8ka-503u","title":"Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Viral load; Medicine; Hazard ratio; Regimen; Antiretroviral therapy; Internal medicine; Immunology; Human immunodeficiency virus (HIV); Virology; Gastroenterology; Confidence interval","score_opus":0.10527197483588475,"score_gpt":0.41841108543661076,"score_spread":0.313139110600726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058157173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754673,0.000456295,0.000013192091,0.000112371556,0.00010334941,0.0011211525,0.00043179496,0.000015468499,0.00019966716],"genre_scores_gemma":[0.99914336,0.0002767793,0.00011753523,0.000028210789,0.000028453704,0.000035741625,0.000228831,0.000013032215,0.00012803945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970481,0.0010031875,0.001237857,0.0003401984,0.00009839582,0.00027227684],"domain_scores_gemma":[0.9960547,0.0028063427,0.0007530656,0.00022028341,0.00012172518,0.000043852757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001193548,0.00018591365,0.0010780002,0.00010219935,0.000047119214,0.000005836406,0.00008690971,0.00021488413,0.00010095563],"category_scores_gemma":[0.0010456627,0.00012493874,0.000113423856,0.00012873804,0.0002758005,0.00009682934,0.000026837686,0.00033318417,0.00008281946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007569657,0.0033683982,0.9608217,0.0000181366,0.00016924144,0.0000014048513,0.00011852998,0.000026563583,0.003981707,0.000021223319,0.0002817779,0.023621695],"study_design_scores_gemma":[0.021460589,0.0071187923,0.9333156,0.00009570983,0.00003859939,2.5139923e-7,0.00002331125,0.0000055403802,0.036933377,0.00001316416,0.0008789873,0.00011613127],"about_ca_topic_score_codex":0.000015973554,"about_ca_topic_score_gemma":0.000027835044,"teacher_disagreement_score":0.03295167,"about_ca_system_score_codex":0.000044501485,"about_ca_system_score_gemma":0.00009058694,"threshold_uncertainty_score":0.5094854},"labels":[],"label_agreement":null},{"id":"W2063088890","doi":"10.1310/hct1205-275","title":"Vitamin D Supplementation Does Not Increase Immunogenicity of Seasonal Influenza Vaccine in HIV-Infected Adults","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Immunogenicity; Medicine; Seroconversion; Influenza vaccine; Vitamin; Human immunodeficiency virus (HIV); Population; Virology; Immunology; Physiology; Internal medicine; Antibody; Environmental health; Vaccination","score_opus":0.18292417760403892,"score_gpt":0.46779409425391555,"score_spread":0.2848699166498766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063088890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964709,0.00013012608,0.00004563076,0.0006326344,0.00022425984,0.0015593449,0.00047133665,0.000050905746,0.00041482924],"genre_scores_gemma":[0.9962701,0.00051819615,0.0018762883,0.0003906041,0.00037592562,0.00011758048,0.00016628714,0.000026388609,0.00025858814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927984,0.0024608215,0.0031692826,0.00050013047,0.0006295562,0.00044183244],"domain_scores_gemma":[0.9911868,0.0067636236,0.0007505675,0.0005460128,0.0004573062,0.00029571488],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012210919,0.0002584499,0.0017801293,0.00024623005,0.000054754844,0.000009798458,0.00021139503,0.00023003647,0.0018708345],"category_scores_gemma":[0.054170065,0.00016964939,0.00049338845,0.00039056808,0.00019224793,0.0001384933,0.00025137898,0.000494839,0.00011304687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020880898,0.0019551434,0.9582164,0.00025454612,0.000485098,0.0000693324,0.00052960933,4.226307e-7,0.008948114,0.00008795367,0.0033839245,0.0051885224],"study_design_scores_gemma":[0.036051393,0.0010659719,0.93464375,0.00041300498,0.00025719224,0.0000041444114,0.00030806806,0.000070936156,0.026566768,0.00012783353,0.00031845155,0.00017246412],"about_ca_topic_score_codex":0.0005570003,"about_ca_topic_score_gemma":0.00021267254,"teacher_disagreement_score":0.041959144,"about_ca_system_score_codex":0.00008189835,"about_ca_system_score_gemma":0.00026455565,"threshold_uncertainty_score":0.9990416},"labels":[],"label_agreement":null},{"id":"W2068181643","doi":"10.1310/hct0805-311","title":"An Estimate of the Proportion of Symptoms Reported in Self-Administered Questionnaires That Are Captured as Adverse Drug Events in an Observational Database","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Interquartile range; Diarrhea; Nausea; Adverse effect; Cohort; Observational study; Cohort study; Pediatrics; Internal medicine","score_opus":0.5661113770237269,"score_gpt":0.6173921826787941,"score_spread":0.05128080565506721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068181643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960445,0.000052162377,0.00003548283,0.00057099364,0.0018118839,0.0010975467,0.00024161006,0.000043322772,0.00010248103],"genre_scores_gemma":[0.9984947,0.00009564741,0.0001906068,0.00051966315,0.00031558858,0.00004430383,0.00025389923,0.000016412358,0.00006918939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99314797,0.0030863006,0.0026858193,0.0004178709,0.00036388138,0.00029813594],"domain_scores_gemma":[0.99497557,0.0020028101,0.0021545093,0.0004640714,0.0001854251,0.00021762411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016272571,0.00020152397,0.00075408653,0.00016212792,0.00008136867,0.0000037466825,0.00033552767,0.00031401668,0.00016046959],"category_scores_gemma":[0.0031832773,0.00015771466,0.00023924287,0.00039464753,0.00018849708,0.0004593691,0.00005685352,0.00073203695,0.000010523614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002131276,0.0029550977,0.9809415,0.00006146894,0.000108705666,0.000061836945,0.00031593358,0.0010001609,0.0111343395,0.00023576632,0.00021807678,0.00083583774],"study_design_scores_gemma":[0.005793002,0.000099938276,0.96415824,0.00018319742,0.0002465129,0.00001121782,0.00031352945,0.0019114221,0.025030445,0.0005148603,0.0015573828,0.00018024986],"about_ca_topic_score_codex":0.00007709548,"about_ca_topic_score_gemma":0.0005243372,"teacher_disagreement_score":0.01678326,"about_ca_system_score_codex":0.00007734051,"about_ca_system_score_gemma":0.0003877093,"threshold_uncertainty_score":0.64314175},"labels":[],"label_agreement":null},{"id":"W2068355743","doi":"10.1310/hct0905-314","title":"A Prospective Study of Body Fat Redistribution, Lipid, and Glucose Parameters in HIV-Infected Patients Initiating Combination Antiretroviral Therapy","year":2008,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University Medical Centre; University Health Network; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Lipodystrophy; Medicine; Prospective cohort study; Internal medicine; Triglyceride; Endocrinology; Antiretroviral therapy; Waist; Lipoatrophy; Diabetes mellitus; Anthropometry; Lipid profile; Stavudine; Metabolic syndrome; Insulin; Human immunodeficiency virus (HIV); Gastroenterology; Cholesterol; Body mass index; Viral load; Immunology","score_opus":0.1445983891358264,"score_gpt":0.4386299770869479,"score_spread":0.2940315879511215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068355743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995851,0.000086749926,0.00005919747,0.00016336281,0.00014024104,0.0034216412,0.0000700833,0.000042943553,0.00016480191],"genre_scores_gemma":[0.9988254,0.00037048664,0.00023773519,0.000065765234,0.00006511953,0.00013355426,0.0002702594,0.000014688669,0.000017023363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99586654,0.0012490704,0.0020147709,0.00039113726,0.00027369746,0.00020480214],"domain_scores_gemma":[0.9963945,0.00207883,0.0007585079,0.0002827144,0.0003429677,0.00014243719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017894752,0.00016429737,0.001019161,0.00015715229,0.00014210577,0.000008651306,0.00005405587,0.00016715126,0.000010774339],"category_scores_gemma":[0.0068084626,0.00013085002,0.00012026114,0.00044284097,0.00012034715,0.000091951566,0.000029705996,0.00030626912,0.000013619139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013750464,0.00899134,0.9852213,0.000015188601,0.00013539928,0.000010002458,0.0005873822,9.418396e-7,0.000033558288,0.000086655426,0.00017767557,0.0033654552],"study_design_scores_gemma":[0.041458853,0.0076601147,0.9498472,0.00011960748,0.00009372412,0.0000030661158,0.00013333271,0.0002401065,0.0001503629,0.00017618207,0.000023525143,0.00009390207],"about_ca_topic_score_codex":0.000065196444,"about_ca_topic_score_gemma":0.0000034674997,"teacher_disagreement_score":0.040083807,"about_ca_system_score_codex":0.000101649,"about_ca_system_score_gemma":0.00009707432,"threshold_uncertainty_score":0.81508577},"labels":[],"label_agreement":null},{"id":"W2069363561","doi":"10.1310/b05e-tfvn-uj8l-mfhj","title":"Attenuated T-Lymphocyte Response to HIV Therapy in Individuals Receiving HMG-CoA Reductase Inhibitors","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Fibrate; Ritonavir; Nelfinavir; HMG-CoA reductase; Statin; Rosuvastatin; Atorvastatin; Internal medicine; Saquinavir; Pharmacology; Indinavir; Protease inhibitor (pharmacology); Integrase inhibitor; Viral load; Immunology; Reductase; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.1986185197320598,"score_gpt":0.4835371366619322,"score_spread":0.2849186169298724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069363561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799179,0.0007434819,0.00004074243,0.014488132,0.0005654673,0.002683369,0.000094347044,0.00011930929,0.0013472448],"genre_scores_gemma":[0.98740804,0.00129603,0.004026791,0.0033224449,0.00036722477,0.00033722413,0.00011107534,0.0000697797,0.0030614005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9887778,0.00622087,0.003254193,0.00077141967,0.00040280184,0.00057291106],"domain_scores_gemma":[0.9889164,0.008610926,0.0005828685,0.0009405333,0.0001850383,0.00076423935],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021515802,0.00031176233,0.0015374697,0.00045116822,0.00015989966,0.00003730734,0.00016169164,0.00043207043,0.0005025737],"category_scores_gemma":[0.036589064,0.00024834712,0.0003591874,0.0011047075,0.00009249104,0.00007907195,0.000039886767,0.0005215269,0.0017350842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028366262,0.007513487,0.6977782,0.00007338047,0.0009715296,0.00039513377,0.002409861,0.000072264105,0.0090469355,0.00047380928,0.13855599,0.11434309],"study_design_scores_gemma":[0.07355297,0.0037297232,0.48384285,0.0017243271,0.00033858026,0.00009999137,0.00036845,0.000056671593,0.0053113224,0.0009153688,0.42922866,0.0008310651],"about_ca_topic_score_codex":0.000034299628,"about_ca_topic_score_gemma":0.000004458593,"teacher_disagreement_score":0.2906727,"about_ca_system_score_codex":0.00030089708,"about_ca_system_score_gemma":0.00089866546,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W2071621051","doi":"10.1310/hag3-8ya5-udqc-36nx","title":"Virologic and Immunologic Response to a Boosted Double-Protease Inhibitor-Based Therapy in Highly Pretreated HIV-1-Infected Patients","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Abbott Canada; Abbott Laboratories","keywords":"Saquinavir; Medicine; Lopinavir; Regimen; Protease inhibitor (pharmacology); Internal medicine; Ritonavir; Viral load; Lamivudine; Gastroenterology; Immunology; Odds ratio; Reverse-transcriptase inhibitor; Nelfinavir; Drug resistance; Pharmacology; Virology; Virus; Antiretroviral therapy; Biology","score_opus":0.12595465333192757,"score_gpt":0.40690000416868316,"score_spread":0.2809453508367556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071621051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980963,0.00025556303,0.000013420575,0.013900663,0.0001590207,0.004264613,0.000050426683,0.00020428676,0.00018899002],"genre_scores_gemma":[0.99320513,0.00016233082,0.0016700026,0.0016035978,0.00018376682,0.00038815802,0.00018372334,0.00003632733,0.0025669904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933051,0.002956181,0.0021518988,0.0007571513,0.00034683704,0.00048284733],"domain_scores_gemma":[0.99449867,0.0040417933,0.0003968761,0.0005015405,0.00016240755,0.00039870007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0061432393,0.00041208527,0.0015760625,0.0004274724,0.000086381835,0.000041733456,0.00012483394,0.0004485641,0.00031287858],"category_scores_gemma":[0.008033012,0.00027744533,0.00028807868,0.00057511864,0.00013280699,0.000084058374,0.00007197527,0.0003916694,0.0005326293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22681078,0.0057218475,0.721313,0.000020912408,0.00036128378,0.000188711,0.00027878126,0.000016459744,0.0050944244,0.000008796261,0.0055964477,0.034588564],"study_design_scores_gemma":[0.1412928,0.0055867825,0.8178546,0.0003092711,0.0001860229,0.000004084556,0.000024093157,0.0001324938,0.009393724,0.000023155344,0.024717316,0.00047565086],"about_ca_topic_score_codex":0.000010069106,"about_ca_topic_score_gemma":0.0000073384717,"teacher_disagreement_score":0.09654162,"about_ca_system_score_codex":0.00019067,"about_ca_system_score_gemma":0.00027649372,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W2078593189","doi":"10.1310/2xvk-pbgl-735n-wh72","title":"Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations","year":2006,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Enfuvirtide; Ritonavir; Concomitant; Medicine; Protease inhibitor (pharmacology); Lopinavir; Regimen; Viral load; Pharmacology; Internal medicine; Protease; Virology; Human immunodeficiency virus (HIV); Immunology; Gp41; Antiretroviral therapy; Biology; Enzyme","score_opus":0.47053954744420085,"score_gpt":0.5174414029777028,"score_spread":0.04690185553350196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078593189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057480697,0.85687804,0.000038052814,0.004828272,0.00082000473,0.046828702,0.03226652,0.00034120833,0.0005185052],"genre_scores_gemma":[0.00013402652,0.9674606,0.008697753,0.000050433253,0.00028893218,0.0009819973,0.021045294,0.00009313971,0.00124787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879429,0.0050645634,0.004814952,0.0013370857,0.00040571066,0.00043483067],"domain_scores_gemma":[0.9836466,0.011746919,0.0025078866,0.0013904993,0.00022738361,0.00048071216],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036636824,0.00080332125,0.0065315263,0.00044823939,0.00009052298,0.000068748814,0.00022689716,0.0005778226,0.00016699274],"category_scores_gemma":[0.011419769,0.0004957747,0.00032777505,0.0006985502,0.000403882,0.00021111681,0.00019175178,0.0005436824,0.000029493915],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018325273,0.004362983,0.005377381,0.00085070956,0.0019779776,0.00033399728,0.00027443146,1.7595914e-7,0.0000019391996,0.000011586813,0.0068333303,0.978143],"study_design_scores_gemma":[0.017168665,0.0013507655,0.00038270326,0.009739674,0.004981916,0.00007881435,0.00017338539,0.000016819598,0.000053775846,0.0000067231035,0.9655459,0.0005008613],"about_ca_topic_score_codex":0.000060742477,"about_ca_topic_score_gemma":0.00017823605,"teacher_disagreement_score":0.9776421,"about_ca_system_score_codex":0.00034088272,"about_ca_system_score_gemma":0.0024894092,"threshold_uncertainty_score":0.99974936},"labels":[],"label_agreement":null},{"id":"W2085481779","doi":"10.1310/hct1105-260","title":"A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Saskatchewan","keywords":"Raltegravir; Abacavir; Medicine; Lamivudine; Adverse effect; Viral load; Internal medicine; Discontinuation; Gastroenterology; Human immunodeficiency virus (HIV); Virology; Chronic hepatitis; Antiretroviral therapy","score_opus":0.15240359952108895,"score_gpt":0.4151683571378847,"score_spread":0.26276475761679574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085481779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281836,0.000022646453,0.0000017128648,0.00094966847,0.0010431497,0.004095298,0.00012355045,0.000025249674,0.00092036335],"genre_scores_gemma":[0.9968096,0.000064798245,0.00024164838,0.000059071805,0.0003263652,0.000058849597,0.000069791786,0.00002402137,0.00234583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934268,0.0015279431,0.0037220982,0.0005125159,0.0005380371,0.00027257664],"domain_scores_gemma":[0.992402,0.005358677,0.0012320839,0.00067628064,0.00016898983,0.00016195934],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068745483,0.00028214636,0.0019759445,0.00019201773,0.000052705123,0.000014439263,0.0001980076,0.0001668719,0.000058215777],"category_scores_gemma":[0.028260175,0.00016314747,0.00029984835,0.00048594215,0.0002534496,0.00007379158,0.00014895327,0.00066906615,0.000022946424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14478958,0.024604918,0.8188484,0.00004475143,0.00040310263,0.000017908536,0.0006508117,3.8456974e-7,0.00091186224,0.00004860762,0.0032670903,0.00641259],"study_design_scores_gemma":[0.3551731,0.015292361,0.6270727,0.00021707106,0.00055679376,0.0000012046759,0.00019293503,0.000015445225,0.0005848349,0.000086499866,0.00062609825,0.00018097063],"about_ca_topic_score_codex":0.000103450846,"about_ca_topic_score_gemma":0.000254049,"teacher_disagreement_score":0.21038352,"about_ca_system_score_codex":0.000023421964,"about_ca_system_score_gemma":0.00019847337,"threshold_uncertainty_score":0.9799252},"labels":[],"label_agreement":null},{"id":"W2085670377","doi":"10.1310/hct1504-161","title":"Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial","year":2014,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University Medical Centre; University Health Network; Ottawa Hospital; Vancouver Infectious Diseases Centre; Université de Montréal; AIDS Vancouver; Concordia University; McGill University Health Centre; McGill University; HIV Legal Network; University of Toronto; Royal Victoria Hospital","funders":"","keywords":"Medicine; Ribavirin; Citalopram; Internal medicine; Placebo; Randomized controlled trial; Hepatitis C; Depression (economics); Pegylated interferon; Hepatitis C virus; Immunology; Antidepressant","score_opus":0.28603039124867446,"score_gpt":0.5005123531631583,"score_spread":0.21448196191448388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085670377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96450746,0.00067473477,0.0017015566,0.0010741984,0.00046101236,0.031045089,0.00006272046,0.000047262176,0.00042595543],"genre_scores_gemma":[0.9926032,0.0021648665,0.00054751703,0.00016730942,0.00046428255,0.0037331379,0.00010223388,0.000038214435,0.0001792747],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98242897,0.011654045,0.0043747923,0.0005532304,0.00058340555,0.00040554334],"domain_scores_gemma":[0.91003484,0.08704709,0.0018399918,0.00040462386,0.0004618573,0.0002116048],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.050342172,0.00030499528,0.0036680226,0.00029855364,0.000118111464,0.00009113136,0.00022409929,0.00043479048,0.00026564804],"category_scores_gemma":[0.12196291,0.00017746536,0.00082795403,0.0002526069,0.00046877196,0.00017352567,0.00011227311,0.00059414556,0.000015093578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96778756,0.00065657997,0.012438361,0.0000777953,0.0008369592,0.0000032957776,0.00027127808,0.0000070628257,0.0011579066,0.00009451476,0.00012667656,0.016541982],"study_design_scores_gemma":[0.9782,0.0020527141,0.0011244385,0.00074165745,0.0005223498,0.0000020603022,0.00003392293,0.01449199,0.002116107,0.00029211445,0.00025411136,0.00016851947],"about_ca_topic_score_codex":0.00010320001,"about_ca_topic_score_gemma":0.00009727455,"teacher_disagreement_score":0.07539305,"about_ca_system_score_codex":0.000036472935,"about_ca_system_score_gemma":0.00030980582,"threshold_uncertainty_score":0.97787255},"labels":[],"label_agreement":null},{"id":"W2089422405","doi":"10.1310/0xh7-f2v2-1k0r-nu2w","title":"Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; St. Paul's Hospital","funders":"","keywords":"Medicine; Enfuvirtide; Regimen; Internal medicine; Confidence interval; Odds ratio; Viral load; Randomization; Logistic regression; Clinical trial; Human immunodeficiency virus (HIV); Immunology","score_opus":0.08973515316492171,"score_gpt":0.4063030425292003,"score_spread":0.3165678893642786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089422405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937641,0.00018783836,0.00016988296,0.002790678,0.000104185536,0.0021540807,0.00013002811,0.000088868896,0.00061034726],"genre_scores_gemma":[0.98521256,0.0001047867,0.008016078,0.00026186815,0.00019519209,0.00007832785,0.00035401853,0.000035222336,0.00574197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968694,0.00041313787,0.0015505815,0.00043869735,0.00044408382,0.00028413642],"domain_scores_gemma":[0.9961369,0.002147895,0.0005457499,0.0003577649,0.00036759643,0.0004440777],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012240176,0.00023883986,0.0012023839,0.000098612785,0.000046896217,0.0000108748445,0.00007692142,0.0000786335,0.00025841524],"category_scores_gemma":[0.008850142,0.00014995794,0.00026523022,0.00020022754,0.000120235665,0.000098696815,0.000036761296,0.00015224399,0.00020244354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005553167,0.0019840945,0.9554344,0.00006121382,0.0003973451,0.000046805948,0.00008622569,0.000014545117,0.000013275596,0.000023400411,0.0027638788,0.033621658],"study_design_scores_gemma":[0.025953643,0.0005976517,0.9629265,0.0007716229,0.0012248548,7.6888983e-7,0.000032483462,0.00011466347,0.00025394355,0.000028539955,0.007872788,0.00022251118],"about_ca_topic_score_codex":5.275696e-7,"about_ca_topic_score_gemma":6.5472375e-7,"teacher_disagreement_score":0.033399146,"about_ca_system_score_codex":0.000051284223,"about_ca_system_score_gemma":0.000259406,"threshold_uncertainty_score":0.9994987},"labels":[],"label_agreement":null},{"id":"W2094521579","doi":"10.1310/hct1206-313","title":"Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"ACT Government","keywords":"Medicine; Darunavir; Ritonavir; Coinfection; Internal medicine; Incidence (geometry); Adverse effect; Lopinavir; Hepatitis C; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.13167708687691224,"score_gpt":0.3890928780651015,"score_spread":0.25741579118818925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094521579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518764,0.00006389252,0.000007158169,0.00053889723,0.00024145996,0.0022884363,0.00036316866,0.000025743122,0.001283632],"genre_scores_gemma":[0.99608856,0.00079733797,0.0002635543,0.000079538906,0.00017087928,0.00007622677,0.00040764915,0.00003351665,0.0020827437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371123,0.0025735176,0.0025902202,0.00047551497,0.00035978778,0.00028975485],"domain_scores_gemma":[0.97945184,0.01878337,0.0009005039,0.00054132455,0.00010908465,0.00021389805],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0058112415,0.000376435,0.0021959676,0.00011870081,0.00006303688,0.0000064067,0.000116139985,0.00023236277,0.0004208507],"category_scores_gemma":[0.010716122,0.00020441301,0.00039770367,0.00019800042,0.0002599625,0.000039940147,0.00007767932,0.00022755822,0.00015134622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0281526,0.0057039256,0.8866084,0.00010644697,0.000641729,0.000051288203,0.00061730866,2.323515e-7,0.00023562658,0.00004951438,0.0011939455,0.07663896],"study_design_scores_gemma":[0.06925373,0.01127573,0.8948661,0.0011050005,0.0015150949,0.000004659779,0.000027797423,0.000066834364,0.014770226,0.000021477492,0.0067908405,0.000302506],"about_ca_topic_score_codex":0.00002071581,"about_ca_topic_score_gemma":0.0000070259084,"teacher_disagreement_score":0.07633645,"about_ca_system_score_codex":0.00013051456,"about_ca_system_score_gemma":0.00010580474,"threshold_uncertainty_score":0.99761707},"labels":[],"label_agreement":null},{"id":"W2097226982","doi":"10.1310/hct1206-323","title":"Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Dermatological and COVID-19 studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadians Living with HIV; University of Toronto; University Health Network; St. Michael's Hospital; Maple Leaf Medical Clinic; Women's College Hospital","funders":"","keywords":"Medicine; Anxiety; Depression (economics); Randomized controlled trial; Quality of life (healthcare); Internal medicine; Lipoatrophy; Human immunodeficiency virus (HIV); Patient satisfaction; Physical therapy; Surgery; Viral load; Antiretroviral therapy; Psychiatry; Immunology","score_opus":0.5745653611812509,"score_gpt":0.45863819170432824,"score_spread":0.11592716947692266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097226982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225944,0.0006951653,0.00034758504,0.0027197094,0.0008689154,0.0018933692,0.00033402772,0.000059785685,0.0008219804],"genre_scores_gemma":[0.9940589,0.0019319943,0.0006729574,0.00069048844,0.00030363968,0.00011986552,0.000017836195,0.000019111594,0.0021851775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676603,0.00057111273,0.0018856247,0.0002764752,0.00024309206,0.00025768814],"domain_scores_gemma":[0.9826,0.015842423,0.0007894354,0.00041693074,0.00022586178,0.00012536492],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019957144,0.00019315514,0.0019411593,0.000041704734,0.00007220473,0.0000058131395,0.00014096923,0.00020888117,0.0001751872],"category_scores_gemma":[0.018861307,0.00009372795,0.0014880021,0.00012926523,0.000295494,0.000031217653,0.000034726883,0.00009608334,0.000036203168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040131096,0.010522034,0.86610067,0.00021189543,0.008748658,0.00006382607,0.0020030083,0.0000024810101,0.00084205205,0.0022312563,0.041788857,0.027354142],"study_design_scores_gemma":[0.09755395,0.019312873,0.76693803,0.00035192983,0.009904089,0.00000886053,0.0012515131,0.00015383438,0.00879708,0.0064928755,0.08867841,0.00055657094],"about_ca_topic_score_codex":0.00006373493,"about_ca_topic_score_gemma":0.000011129207,"teacher_disagreement_score":0.09916269,"about_ca_system_score_codex":0.000025135936,"about_ca_system_score_gemma":0.000081487684,"threshold_uncertainty_score":0.98940325},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2105543437","doi":"10.1179/1528433614z.0000000015","title":"Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)","year":2015,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regimen; Lamivudine; Adverse effect; Emtricitabine; Internal medicine; Viral load; Surgery; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Chronic hepatitis","score_opus":0.3198417514449129,"score_gpt":0.47750882426556046,"score_spread":0.15766707282064757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105543437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96913016,0.0005576324,0.0000066427747,0.023255287,0.00029178918,0.0028881652,0.00023637948,0.000058335158,0.0035756384],"genre_scores_gemma":[0.99331653,0.0008954185,0.001276269,0.0006333952,0.0005302722,0.0001579061,0.00018280081,0.000026706062,0.002980675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99222916,0.0038394474,0.002098625,0.00094377773,0.0005005719,0.00038841678],"domain_scores_gemma":[0.98680955,0.011495101,0.0005291464,0.0006526523,0.000083437866,0.00043011399],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008785741,0.00037572556,0.001679557,0.00009303346,0.00013378361,0.000066214016,0.00015874334,0.000280292,0.0000996471],"category_scores_gemma":[0.015227756,0.00019778124,0.00023846028,0.00023019813,0.0002106395,0.00011123361,0.00020191923,0.0003976243,0.00011829516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.102435865,0.017466467,0.55669034,0.000012526077,0.00367514,0.0037950214,0.037099876,0.0000037889106,0.0006918264,0.0001780741,0.15503958,0.12291151],"study_design_scores_gemma":[0.15962659,0.010760904,0.6970369,0.00091481383,0.0022470227,0.000041750343,0.03765026,0.00020605193,0.0024484266,0.0015429991,0.08668858,0.0008356581],"about_ca_topic_score_codex":0.00046235425,"about_ca_topic_score_gemma":0.00014896989,"teacher_disagreement_score":0.14034662,"about_ca_system_score_codex":0.00057258696,"about_ca_system_score_gemma":0.0002873235,"threshold_uncertainty_score":0.9930674},"labels":[],"label_agreement":null},{"id":"W2111884657","doi":"10.1310/hct1306-335","title":"Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Abacavir; Darunavir; Emtricitabine; Lamivudine; Regimen; Ritonavir; Internal medicine; Gastroenterology; Viral load; Creatinine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Hepatitis B virus; Virus","score_opus":0.17419158608269425,"score_gpt":0.4424751159049179,"score_spread":0.26828352982222364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111884657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95611507,0.002858878,0.00093399547,0.026552523,0.0007419895,0.0077295243,0.00016440869,0.0002746171,0.0046289735],"genre_scores_gemma":[0.96252054,0.0014219383,0.0099937515,0.0008413733,0.0011657448,0.00049689226,0.00079195783,0.00008994035,0.022677844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996468,0.0006923368,0.0014680673,0.0005023481,0.00038347326,0.00048576482],"domain_scores_gemma":[0.9936095,0.0048454227,0.0005065991,0.000418772,0.00015602972,0.0004636967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060703023,0.00035688197,0.0015078897,0.00011796348,0.0001587894,0.000037619793,0.000097251934,0.00028680565,0.00013037212],"category_scores_gemma":[0.0022355975,0.00023034531,0.0002998275,0.00018732496,0.0001770894,0.00015961987,0.000041816565,0.00026687697,0.00015201721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04579486,0.012956826,0.3058602,0.00024387224,0.00435702,0.000098330805,0.0019785175,0.0000014223632,0.0014860604,0.004061403,0.07940871,0.5437528],"study_design_scores_gemma":[0.20441689,0.005160019,0.252421,0.00056836003,0.0021392587,0.0001226286,0.0003375295,0.0002187961,0.0034350306,0.00066411623,0.529419,0.001097385],"about_ca_topic_score_codex":0.0000028680183,"about_ca_topic_score_gemma":0.0000019795264,"teacher_disagreement_score":0.5426554,"about_ca_system_score_codex":0.00006916757,"about_ca_system_score_gemma":0.00014102847,"threshold_uncertainty_score":0.9393209},"labels":[],"label_agreement":null},{"id":"W2122378285","doi":"10.1310/hct0806-421","title":"Evaluation of Stool Frequency and Stool Form as Measures of HIV-Related Diarrhea","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Health Sciences Centre; Sinai Health System; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"University of Toronto; Innovative Research Group Project of the National Natural Science Foundation of China; University Health Network","keywords":"Diarrhea; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Gastroenterology; Prospective cohort study; Antiretroviral therapy; Correlation; Viral load; Immunology","score_opus":0.3488472668489003,"score_gpt":0.5262927517135569,"score_spread":0.17744548486465667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122378285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97881895,0.0025348172,0.00048058573,0.0011873645,0.0002549937,0.0024200121,0.00006938445,0.000040105933,0.014193776],"genre_scores_gemma":[0.99739015,0.00063350535,0.0013326401,0.000096943084,0.000114196766,0.00004049675,0.00007547409,0.00001958757,0.00029698585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941494,0.0011878608,0.003218294,0.00032917433,0.0008775145,0.00023778262],"domain_scores_gemma":[0.9926909,0.0043653804,0.0011171644,0.00050590426,0.0010278223,0.00029278634],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03698162,0.00015884565,0.0011789406,0.00017834452,0.00007148469,0.000004697927,0.00007953054,0.00036097827,0.0004129646],"category_scores_gemma":[0.023577398,0.00012044606,0.00028200995,0.00028631504,0.0001756512,0.00006698668,0.000023177923,0.0002852675,0.000117368465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029624046,0.0042315023,0.3032378,0.00033090852,0.0024600097,0.000021636353,0.0010127134,0.000019139981,0.0032160992,0.012914515,0.0032700454,0.66632324],"study_design_scores_gemma":[0.045059234,0.0032348349,0.90500474,0.0011641135,0.0067614936,0.00004584981,0.0002155722,0.0010264812,0.002632581,0.031327665,0.0031799593,0.00034750297],"about_ca_topic_score_codex":0.00007430066,"about_ca_topic_score_gemma":0.000017504954,"teacher_disagreement_score":0.66597575,"about_ca_system_score_codex":0.00009347411,"about_ca_system_score_gemma":0.0005635076,"threshold_uncertainty_score":0.9916301},"labels":[],"label_agreement":null},{"id":"W2136451994","doi":"10.1310/7lyw-gqff-wprq-k3qw","title":"Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; Health Sciences Centre; Canadians Living with HIV; Sunnybrook Health Science Centre; University of Waterloo; University Health Network; University of Toronto; Montreal General Hospital; McGill University","funders":"Abbott Laboratories","keywords":"Lopinavir; Medicine; Amprenavir; Ritonavir; Regimen; Salvage therapy; Internal medicine; Hazard ratio; Atazanavir; Lopinavir/ritonavir; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Confidence interval; Immunology; Protease; Chemotherapy; HIV-1 protease","score_opus":0.20446275338973807,"score_gpt":0.483843551421669,"score_spread":0.27938079803193094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136451994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463326,0.00069192535,0.000031690925,0.00030998883,0.0002354994,0.0023120437,0.000045042416,0.000045992452,0.0016945818],"genre_scores_gemma":[0.992366,0.0010003131,0.003631146,0.00009859479,0.00047991774,0.00006334602,0.00004965389,0.000046658573,0.0022643642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936108,0.001531523,0.0033611734,0.00061585085,0.0004955853,0.00038507706],"domain_scores_gemma":[0.9942107,0.003316389,0.0012764317,0.00053598534,0.00020391293,0.0004565679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008796408,0.00037358183,0.0025497484,0.000109130015,0.00006773002,0.000022689841,0.000105162544,0.00032508827,0.00022898774],"category_scores_gemma":[0.005136954,0.0002236263,0.0008328555,0.0002769751,0.0005172547,0.00012369792,0.000044616478,0.00044610244,0.000034434706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012170236,0.0021938635,0.957266,0.00008997108,0.0010578965,0.00009241288,0.00010769394,7.9403736e-7,0.0006860379,0.00018645907,0.0014503609,0.024698315],"study_design_scores_gemma":[0.24944901,0.05073906,0.59939,0.0051628766,0.0025644465,0.00020470747,0.00039895758,0.00004361686,0.052188985,0.00086392346,0.037306614,0.0016878123],"about_ca_topic_score_codex":0.00004134416,"about_ca_topic_score_gemma":0.000001756884,"teacher_disagreement_score":0.35787597,"about_ca_system_score_codex":0.00003950076,"about_ca_system_score_gemma":0.00085663784,"threshold_uncertainty_score":0.91192156},"labels":[],"label_agreement":null},{"id":"W2143379599","doi":"10.1310/fgmf-y0ly-dmx8-371v","title":"Predictors of Long-Term Immunological Outcome in Rebounding Patients on Protease Inhibitor-Based HAART After Initial Successful Virologic Suppression: Implications for Timing to Switch","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; Bayer Corporation","keywords":"Medicine; Viremia; Viral load; Internal medicine; Protease inhibitor (pharmacology); Univariate analysis; Gastroenterology; Reverse-transcriptase inhibitor; Immunology; Retrospective cohort study; Multivariate analysis; Area under the curve; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.22046669565469398,"score_gpt":0.4709658042581454,"score_spread":0.25049910860345137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143379599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348956,0.00012556183,0.00041583346,0.0006111028,0.00081727694,0.003676744,0.00069545506,0.000039269114,0.0001291857],"genre_scores_gemma":[0.9969977,0.000012619465,0.00027665592,0.00024207354,0.0000828488,0.0018031686,0.00042450146,0.000019232386,0.00014121455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993585,0.0030181415,0.002118612,0.0006137279,0.000091924536,0.00057261105],"domain_scores_gemma":[0.99241215,0.006413454,0.0004149887,0.00049520156,0.00014023649,0.00012396048],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043369895,0.00026204615,0.0010890219,0.00023015718,0.00015294012,0.000023439507,0.0002662027,0.0005375186,0.0005053266],"category_scores_gemma":[0.020029424,0.0001814318,0.00043103955,0.00019115169,0.00024798515,0.00006574876,0.000085803535,0.00045244806,0.00027693657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071782493,0.002479043,0.9819005,0.00003083731,0.00013062409,0.000010394511,0.000028467499,0.00000639202,0.0035296322,0.00007124354,0.000484935,0.004149665],"study_design_scores_gemma":[0.014268904,0.0038953694,0.963162,0.00015513673,0.00007972947,0.000001660923,0.000011215495,5.552803e-7,0.01640566,0.00012761442,0.0016808093,0.00021133691],"about_ca_topic_score_codex":0.0000065841227,"about_ca_topic_score_gemma":0.000007628474,"teacher_disagreement_score":0.01873851,"about_ca_system_score_codex":0.00008749859,"about_ca_system_score_gemma":0.0001564827,"threshold_uncertainty_score":0.9882253},"labels":[],"label_agreement":null},{"id":"W2144136328","doi":"10.1310/hct1105-312","title":"A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; College of Medicine, University of Cincinnati; University at Buffalo; University of California, San Diego; BioCryst; Deutsches Krebsforschungszentrum; International AIDS Society; University of Cincinnati; Johns Hopkins University; ACT Government; Georgia Clinical and Translational Science Alliance; Tulane University; University of Minnesota; University of Rochester; University of Miami; Northwestern University; York University; Bristol-Myers Squibb; University of Pennsylvania; Gilead Sciences; Vanderbilt University; Emory University; University of Nebraska Medical Center; National Institutes of Health; Ohio State University; University of Southern California; GlaxoSmithKline","keywords":"Medicine; Abacavir; Zidovudine; Regimen; Internal medicine; Lamivudine; Clinical endpoint; Placebo; Viral load; Indinavir; Population; Efavirenz; Discontinuation; Adverse effect; Gastroenterology; Randomized controlled trial; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus; Pathology","score_opus":0.06691439298854879,"score_gpt":0.3846769090118663,"score_spread":0.3177625160233175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144136328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97358584,0.000022211427,0.000076900615,0.0038426374,0.0005273025,0.020209849,0.0000115970215,0.00008788593,0.0016357794],"genre_scores_gemma":[0.99295247,0.000054929966,0.0018269756,0.00015016636,0.00061056204,0.0027632099,0.00014342113,0.000033683224,0.0014646089],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912134,0.0037479731,0.003521409,0.00067385245,0.0005082809,0.00033511987],"domain_scores_gemma":[0.98334974,0.013878566,0.0016716096,0.0005840738,0.0002511042,0.00026488275],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017668495,0.000377157,0.0041034836,0.00033063197,0.00005658979,0.00002091651,0.00012391216,0.00047886308,0.00013078096],"category_scores_gemma":[0.05392823,0.0002079982,0.00070972956,0.0002553069,0.00026527894,0.00008248122,0.000042888718,0.000863389,0.00008936341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9889856,0.0027008005,0.0024888534,0.00003432045,0.00041551207,0.000071082555,0.0004188937,0.0000027410763,0.0011744638,0.00014735264,0.00045914808,0.0031012155],"study_design_scores_gemma":[0.9913904,0.0029361385,0.0009821963,0.00091224886,0.0006707912,0.000007899755,0.0001267402,0.00056385604,0.0018267985,0.000106308435,0.00026500062,0.00021159044],"about_ca_topic_score_codex":0.000013602551,"about_ca_topic_score_gemma":0.000016631677,"teacher_disagreement_score":0.036259733,"about_ca_system_score_codex":0.000049625396,"about_ca_system_score_gemma":0.00036853933,"threshold_uncertainty_score":0.95404094},"labels":[],"label_agreement":null},{"id":"W2152778462","doi":"10.1310/hct1004-207","title":"Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Enfuvirtide; Medicine; Discontinuation; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Tenofovir; Internal medicine; Immunology; Viral load","score_opus":0.16061886623418828,"score_gpt":0.46734059060930044,"score_spread":0.30672172437511214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152778462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987904,0.0001477299,0.00010868983,0.0065231016,0.00013652456,0.0014201071,0.00004609446,0.000077717705,0.003636018],"genre_scores_gemma":[0.9917169,0.00018139965,0.0018880673,0.00025555055,0.00019792444,0.000030746654,0.00034916634,0.000015016756,0.005365192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950451,0.0011648043,0.002766634,0.00038588917,0.00036422338,0.00027330682],"domain_scores_gemma":[0.9961684,0.0025938055,0.00061940827,0.00033752515,0.00009998762,0.00018088271],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0060385084,0.00021714016,0.0016479216,0.0002447138,0.00002615641,0.000016083952,0.00008785574,0.00023144043,0.00031558823],"category_scores_gemma":[0.010768692,0.00015663996,0.00037343198,0.0004507111,0.000066868924,0.00009181553,0.000022697192,0.000234496,0.00019609343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011034822,0.0025817025,0.9505733,0.000017006016,0.0002652823,0.000048132613,0.0003346791,0.0000030286744,0.0010030577,0.0003474825,0.008599215,0.035123628],"study_design_scores_gemma":[0.017773824,0.00071964436,0.9704337,0.00045702604,0.0004021248,0.0000039267793,0.00004387056,0.00005368535,0.0061471784,0.00073117396,0.0030465757,0.00018723834],"about_ca_topic_score_codex":0.0000059111617,"about_ca_topic_score_gemma":0.000007844313,"teacher_disagreement_score":0.03493639,"about_ca_system_score_codex":0.000060032384,"about_ca_system_score_gemma":0.00019841586,"threshold_uncertainty_score":0.997564},"labels":[],"label_agreement":null},{"id":"W2163692526","doi":"10.1310/vqxj-41x6-gja2-h6ag","title":"Effect of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Survival in HIV-Associated Advanced Kaposi's Sarcoma Patients Treated with Chemotherapy","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Vincristine; Regimen; Sarcoma; Gastroenterology; Indinavir; Chemotherapy regimen; Anthracycline; Protease inhibitor (pharmacology); Surgery; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Cyclophosphamide; Pathology; Cancer","score_opus":0.044704020480735865,"score_gpt":0.37712422728603234,"score_spread":0.3324202068052965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163692526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942033,0.000078157645,0.000007874055,0.00029217292,0.00022012403,0.004013898,0.00014864242,0.00008579076,0.000950026],"genre_scores_gemma":[0.998538,0.00013506433,0.000058931557,0.0005841131,0.0000794075,0.00017424431,0.00021212726,0.00007716719,0.00014090634],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912817,0.0051813745,0.0016794226,0.00065364817,0.00069402996,0.0005098642],"domain_scores_gemma":[0.9940592,0.0038659358,0.0011967062,0.00042201922,0.00021962759,0.00023649682],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005176415,0.00046789978,0.0025440322,0.0001997688,0.00006405505,0.000017187433,0.00012535203,0.00045847063,0.0000902813],"category_scores_gemma":[0.008744773,0.0003112251,0.0006129069,0.0006977908,0.0001875857,0.00009013244,0.000007826146,0.0005518983,0.000014330251],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12333012,0.004901773,0.83319354,0.00004986627,0.00044136972,0.000023308892,0.00006113292,0.000038734466,0.0019503345,0.000018560886,0.00041294555,0.035578303],"study_design_scores_gemma":[0.39105102,0.0883302,0.3880407,0.0009943591,0.00030984747,2.8104657e-7,0.000048416543,0.00006259563,0.12989825,0.000039308787,0.00059712515,0.0006278988],"about_ca_topic_score_codex":0.00008200048,"about_ca_topic_score_gemma":0.000013368694,"teacher_disagreement_score":0.44515285,"about_ca_system_score_codex":0.0002906898,"about_ca_system_score_gemma":0.00035738057,"threshold_uncertainty_score":0.99993396},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2317708264","doi":"10.1310/hct1302-90","title":"Relationship of Chronic Hepatitis C Infection to Rates of AIDS-Defining Illnesses in a Canadian Cohort of HIV Seropositive Individuals Receiving Highly Active Antiretroviral Therapy","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Ottawa; Simon Fraser University; McGill University; McGill University Health Centre; Ontario HIV Treatment Network; Women's College Hospital; Maple Leaf Medical Clinic; Public Health Ontario; Canadian AIDS Treatment Information Exchange; St. Paul's Hospital; University of British Columbia; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Multicenter AIDS Cohort Study; Cohort; Internal medicine; Hepatitis C virus; Immunology; Rate ratio; Poisson regression; Hepatitis C; Cohort study; Relative risk; Viral disease; Virology; Human immunodeficiency virus (HIV); Sida; Confidence interval; Virus; Population; Environmental health","score_opus":0.1866082505449775,"score_gpt":0.47778726822010853,"score_spread":0.291179017675131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317708264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957644,0.00032975577,0.00006835084,0.00030745062,0.00034375023,0.0015960839,0.0003909559,0.000015463982,0.0011837947],"genre_scores_gemma":[0.99762315,0.0011793646,0.00057800673,0.00006645024,0.00027401742,0.00008104281,0.00010446267,0.00003403197,0.000059472957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929216,0.0032988703,0.002391296,0.00031117242,0.00054181274,0.0005352544],"domain_scores_gemma":[0.98720574,0.010702734,0.000835374,0.00036204362,0.0004254516,0.00046865066],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014335911,0.0001921557,0.0017046032,0.0008200598,0.00006207472,0.000010972886,0.00012698678,0.00034018236,0.00027978478],"category_scores_gemma":[0.048591364,0.00017190982,0.00028636516,0.0010490455,0.00023926215,0.00028219176,0.000055371904,0.00050612807,0.000043468583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048744367,0.00030011032,0.9690376,0.0000940423,0.00023262012,0.000003366187,0.0007488846,0.000012995954,0.0013283482,0.000427825,0.00023013292,0.02709664],"study_design_scores_gemma":[0.0029472066,0.0016803871,0.9715293,0.00067742134,0.00009758494,0.0000013900775,0.00005981814,0.000031630643,0.022286365,0.00006220466,0.0004871821,0.00013950274],"about_ca_topic_score_codex":0.17141654,"about_ca_topic_score_gemma":0.043144375,"teacher_disagreement_score":0.12827216,"about_ca_system_score_codex":0.00040636543,"about_ca_system_score_gemma":0.0015333247,"threshold_uncertainty_score":0.97431576},"labels":[],"label_agreement":null},{"id":"W2317972666","doi":"10.1080/15284336.2015.1111555","title":"Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles","year":2016,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Viremia; Medicine; Regimen; Virology; Drug resistance; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Viral load; Internal medicine; Immunology; Reverse transcriptase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Polymerase chain reaction; Genetics","score_opus":0.10623582874814227,"score_gpt":0.3866071786211991,"score_spread":0.2803713498730568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317972666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130075,0.00037345546,0.0002798377,0.07457075,0.00044761103,0.0075740716,0.0002639823,0.00011954463,0.0033632738],"genre_scores_gemma":[0.86867136,0.00033927173,0.004372048,0.0010647977,0.0009281181,0.00062801316,0.00006454225,0.000054762513,0.12387709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997332,0.000512367,0.0011963518,0.00043342882,0.00023430685,0.00029154913],"domain_scores_gemma":[0.99047476,0.00837449,0.00047507725,0.00036536963,0.00011687029,0.00019340852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054709325,0.00020442084,0.0010285773,0.000047999438,0.00015930686,0.000028703806,0.0001224578,0.00011846317,0.00016581276],"category_scores_gemma":[0.014084167,0.00008463117,0.00031115994,0.000091512695,0.00024219672,0.000055835946,0.00007093575,0.00007797454,0.00028833095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053078897,0.0014029352,0.3499442,0.00023998981,0.0017928962,0.000028818253,0.0014109513,1.5354163e-7,0.00050106633,0.0033993928,0.44116187,0.14703882],"study_design_scores_gemma":[0.108923525,0.0018994393,0.08407442,0.0026082247,0.0009636803,0.0000034218344,0.00009179208,0.000042508997,0.002588084,0.0022585215,0.79583895,0.0007074484],"about_ca_topic_score_codex":0.0000010795172,"about_ca_topic_score_gemma":0.000003324011,"teacher_disagreement_score":0.35467705,"about_ca_system_score_codex":0.00007283253,"about_ca_system_score_gemma":0.00008771731,"threshold_uncertainty_score":0.9942206},"labels":[],"label_agreement":null},{"id":"W2411587754","doi":"10.1080/15284336.2016.1184827","title":"Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials","year":2016,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic; University of Toronto; Public Health Ontario; University Health Network","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Immune system; Inflammation; Systemic inflammation; Immunology; Tolerability; Probiotic; Population; Placebo; Gut flora; Internal medicine; Adverse effect; Biology; Pathology","score_opus":0.1655538968730954,"score_gpt":0.44157794288070523,"score_spread":0.2760240460076098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411587754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9163924,0.0006428055,0.046618413,0.022876024,0.00018559908,0.013139519,0.00012548281,0.000017420618,0.0000023450696],"genre_scores_gemma":[0.99395216,0.0018213373,0.002652666,0.00011131166,0.00061517966,0.00057102717,0.00009125823,0.000032221582,0.00015281947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947914,0.0019065083,0.0023069596,0.0005614181,0.00009370383,0.00034003137],"domain_scores_gemma":[0.99425256,0.004060485,0.0010693113,0.0003371944,0.00017453205,0.000105938285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02318679,0.00022907097,0.0009851016,0.00007371609,0.00022035952,0.00006726289,0.00013934032,0.00018003408,0.000002995938],"category_scores_gemma":[0.006936357,0.00013284879,0.00011429985,0.00011878408,0.000107941145,0.000019138653,0.00003672383,0.00010025999,9.3342567e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041027283,0.0003662001,0.0022520677,0.0004112347,0.00017470792,1.165249e-7,0.0011741233,0.000020886118,0.9204911,0.00009622347,0.00041236388,0.07049826],"study_design_scores_gemma":[0.10215441,0.0635921,0.36551595,0.005005099,0.0014163567,0.000038561793,0.0042058458,0.0010355124,0.44456863,0.001376189,0.008532302,0.0025590472],"about_ca_topic_score_codex":0.000030390764,"about_ca_topic_score_gemma":0.0012869653,"teacher_disagreement_score":0.47592247,"about_ca_system_score_codex":0.000046225257,"about_ca_system_score_gemma":0.000557796,"threshold_uncertainty_score":0.83039683},"labels":[],"label_agreement":null},{"id":"W4239380123","doi":"10.1310/hct1301-023","title":"High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1&lt;sub&gt;2009&lt;/sub&gt; and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of British Columbia; Dalhousie University; University of Toronto; McGill University; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Immunogenicity; Seroconversion; Dosing; Booster dose; Booster (rocketry); Immunology; Live attenuated influenza vaccine; Influenza vaccine; Immunization; Internal medicine; Vaccination; Virology; Antigen; Human immunodeficiency virus (HIV)","score_opus":0.15416824133214285,"score_gpt":0.4268660800435144,"score_spread":0.27269783871137154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239380123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859465,0.0026980187,0.00039514704,0.00072487193,0.00035014772,0.009320019,0.0003414168,0.00013262959,0.0000912574],"genre_scores_gemma":[0.9923645,0.003025156,0.0020177972,0.00065017,0.0011232337,0.00044691993,0.000096175114,0.000109509594,0.0001665023],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9858701,0.005537793,0.0052976883,0.00097065093,0.0010686334,0.0012551075],"domain_scores_gemma":[0.9766194,0.018762812,0.0021550981,0.001026544,0.0008227251,0.0006134063],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.026128089,0.0007959441,0.007688664,0.00046870235,0.00016355928,0.000051651958,0.00027783206,0.0006505856,0.000120212484],"category_scores_gemma":[0.043980565,0.00047380157,0.0008377106,0.0007656524,0.00074079004,0.00036377567,0.00031941687,0.0012415183,0.000035687557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90975446,0.0014823627,0.024006357,0.00021888867,0.0021547175,0.000020346459,0.00058509276,0.0000012560162,0.055609055,0.000013726693,0.0005155811,0.0056381696],"study_design_scores_gemma":[0.92034113,0.0039838986,0.05934005,0.0014749119,0.001725547,0.000027688164,0.00006546975,0.00026905528,0.011896149,0.000027844262,0.0003035267,0.000544701],"about_ca_topic_score_codex":0.00016766087,"about_ca_topic_score_gemma":0.00017186152,"teacher_disagreement_score":0.043712907,"about_ca_system_score_codex":0.00014566552,"about_ca_system_score_gemma":0.0005085246,"threshold_uncertainty_score":0.99977136},"labels":[],"label_agreement":null}]}